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With the recent increase in the use of minimally invasive surgery in orthopedic 
and reconstructive surgery, there is a rising need for a more efficient method 
of controlling profuse intra-operative bleeding from bone surfaces, and 
effecting bone regeneration at later stages.  
Current methods to combat the problem of profuse bleeding include the use of 
hemostatic materials such as bone wax which have shown to be detrimental to 
bone regeneration and cause unwanted side effects in the long run. These 
hemostatic materials only affect the blood flow and do not aid bone 
regeneration. 
Autologous bone grafts and bone graft substitutes like calcium phosphate 
cements are traditionally used to aid bone regeneration. Autologous bone 
grafts are marred with limited supply and donor site morbidity hence synthetic 
materials for bone regeneration are often used, but they too are faced with 
issues such as biocompatibility and inadequate osteoactive properties. This has 
led to an increasing adoption of alternative methods like the use of bone 
growth factors such as bone morphogenetic proteins to augment traditional 
bone graft materials. However, as profuse bleeding often results in difficulties 
with localized retention of bioactive growth factors and their carriers, this 
could give rise to a need for large doses of growth factors and bone formation 
at unwanted sites which may lead to a failure of reconstructive surgery.  
 x 
This research aims at providing a moldable material which can control bone 
bleeding as well as stimulate bone repair. And to achieve this, the idea is to 
develop a moldable putty made by mixing novel “yolk shell” particles which 
provide a controlled release of pro-hemostatic and growth factors with 
hydroxyapatite using a binding medium supplemented with thrombin. 
Yolk shell particles possess a unique core-void-shell configuration and in this 
research, are synthesized and optimized to not only maintain the 
biofunctionality of BMP-2, but also to provide a sustained release of the 
growth factor. In this work, a self-assembly method followed by a modified 
water in oil emulsion method is used to synthesize silk fibroin yolk shell 
particles. These particles are characterized and optimized for size, loading 
efficiency and the release profile of the incorporated BMP-2. The particles are 
subsequently tested for cytotoxicity, functionality and potency of the released 
BMP-2 and their effect on osteogenic differentiation of C2C12 cells.  
Hydroxyapatite is a well-known osteoconductive material and thrombin a 
known hemostatic agent. The BMP-2 loaded yolk shell particles are mixed 
with hydroxyapatite and subsequently mixed with silk fibroin solution 
supplemented with thrombin to form a moldable putty, which can set or 
harden upon implantation. The putty is optimized for handling properties, 
monitored for release of BMP-2 and is subjected to mechanical tests and 
degradation studies. The hemostatic potential of the putty is also observed 
using a PDMS microchannel device and recording the blood flow by a high 
speed camera. Finally, the putty is tested for cytotoxicity and ability to cause 
and affect osteogenic differentiation of C2C12 cells. 
 xi 
This research shows the development of a moldable putty which can not only 
cause hemostasis upon contact with blood, but also pave way for bone 
regeneration when used during minimally invasive surgical procedures of 
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During minimally invasive orthopedic surgeries, surgical intervention is 
required at two stages; to attain hemostasis and subsequently to implant the 
bone graft or bone graft substitute.  
With the recent increase in the use of “keyhole” or minimally invasive surgery 
(MIS) in orthopedic, maxillo-facial and reconstructive/plastic surgery, there is 
a rising need for a more efficient method of controlling profuse intra-operative 
bleeding from bone surfaces. Current methods to attain hemostasis include the 
use of materials such as bone wax and/or the use of coagulative proteins such 
as thrombin [1, 2]. However, these methods not only include an additional step 
in the surgical process but have also been known to cause bacterial growth and 
inflammation [1, 2]. 
Ensuring complete bone repair post orthopedic surgery is of paramount 
importance to surgeons. Bone repair within the body relies on two main 
processes, osteoinduction and osteoconduction. Osteoinduction is the 
stimulation of undifferentiated cells into osteogenic lineage, while 
osteoconduction is defined as the growth of bony tissue into the structure of an 
implant or a graft [3]. To address this issue, autologous and allogeneic graft 
materials and synthetic bone graft substitutes are used. While autologous bone 
grafts are limited in supply and can cause donor site morbidity, allografts and 
synthetic bone graft substitutes can lead to  unfavorable immunogenic 




Bone Morphogenetic Proteins (BMPs) in conjunction with natural and 
synthetic bone graft substitutes to augment these bone graft materials [5-8]. 
However, this poses a challenge because profuse bleeding often results in 
difficulty in localized retention of bioactive growth factors at the site of 
surgery. This could necessitate large doses of growth factors; bone formation 
at unwanted sites; or the failure of the reconstructive surgery altogether as the 
bone may fail to heal [9]. 
To summarize, the current methods for bone repair are hampered by the 
limited supply of autologous bone grafts and the need for supraphysiological 
loading of growth factors, whereas achieving hemostasis faces the hurdle of 
lack of bulk properties of soluble hemostatic agents and inflammatory 
response of bulk materials such as bone wax.  
Advances in manufacturing techniques are able to fabricate micro and 
nanoscale structures incorporating growth factors and proteins. This may solve 
the problem of supraphysiological loading of osteogenic growth factors to a 
certain extent. However, these nano and micro structures have been known to 
face problems of burst release and being washed away from the site of 
application [10].  
Therefore, there is a need for a biomaterial that will simultaneously ensure 
bone hemostasis and deliver osteogenic growth factors at a joint fusion or 
bone reconstruction site particularly when employing a minimally invasive 
surgical approach. Further, it would be advantageous if the material is 




The following proposal aims to simultaneously circumvent the problems faced 
by current hemostatic and growth factor delivery system by developing a 
moldable putty comprising hydroxyapatite, “yolk shell” particles (YSPs) 
which act as reservoirs for time dependent release of the encapsulated bone 
growth factor, and thrombin (a hemostatic agent).  
1.2 The Idea and Hypothesis 
The development of such a material, as discussed in the previous section, 
would involve the fabrication of a moldable material with a threefold effect 
i.e., a composite that could function as a hemostatic agent, a growth factor 
carrier vehicle and an osteoconductive bulking agent or void filler. Thus, the 
design scheme was devised as a two pronged approach which focused on: 
1) development of delivery vehicles which could deliver the osteogenic 
growth factors in a sustained manner at the required site and,  
2) a method of delivery of these vehicles, along with osteoconductive and 
hemostatic components, in the form of a moldable bulking agent.  
This is aimed to be achieved in the manner of a putty containing novel “yolk 
shell” particles made of silk fibroin (SF), hydroxyapatite (HA) and thrombin. 
Yolk shell particles possess a unique structure that is composed of a shell that 
encapsulates core particles. The idea is to add the growth factor, here BMP-2, 
on the surface of the core of these particles. The core-void-shell configuration 
is believed to circumvent the problem of burst release of growth factors as the 
release from the cores, through the shell, is believed to be more sustained than 
traditional point delivery systems. The yolk shell configuration could also 




which has been reported elsewhere [10, 11]. These particles will then be 
mixed with an osteoconductive material (hydroxyapatite) and this mixture will 
be made into a putty using a binding medium supplemented with a hemostatic 
factor thrombin (Figure 1.1). 
 
 
Figure 1.1: Schematic of the approach. BMP-2 loaded silk fibroin nanoparticles are encapsulated 
within a silk fibroin capsule to form a yolk-shell structure. These particles are then mixed with 
hydroxyapatite and a binding agent (silk fibroin solution and thrombin) is added to form a moldable 







It is hypothesized that a moldable putty made with BMP-2 loaded yolk shell 
particles, hydroxyapatite and thrombin will maintain a sustained release 
profile of BMP-2 promoting osteogenic differentiation of cells; and cause 
clotting of blood upon contact. 
 Hemostasis- Thrombin, a clotting factor, will be responsible for controlling 
the bleeding by promoting rapid clotting of blood  
 Bone repair by growth factor delivery- BMP-2 will be released in a 
controlled and sustained manner from the yolk-shell particles. In addition to 
the growth factors, YSPs are to be mixed with hydroxyapatite which is 
known to be osteoconductive. The combined effect of the growth factors and 
hydroxyapatite is believed to aid in bone repair at the intended site. 
 Potential application for irregular bone defects- The material will be 
moldable and a suitable application device (viz. syringe) can be used to 
apply it at irregular bone defect sites. 
 
As shown previously (Figure 1.1), the proposed methodology involves loading 
the BMP-2 in the structure’s core, made of SF, without the use of organic 
solvents. This core will be further encapsulated within a SF shell. Finally, this 
structure will be mixed with a pro-hemostatic agent and a binding agent to 
form a moldable paste/putty to be applied at the site of surgery. 
The methodology used in the synthesis of the yolk-shell particles aims to 
circumvent the need to use harsh fabrication conditions traditionally 






It is believed that this designed system has the following advantages:  
1) It offers a single delivery system for a multitude of factors augmenting 
hemostasis and bone growth. 
2) The yolk shell structure allows for the elimination of the use of organic 
solvents during synthesis and prevents burst release of the cargo (here 
BMP-2). 
3) Design parameters can be changed at each fabrication step to tune the final 
properties. 
4) Small sample preparation time will be required. The system would need 
minimum sample preparation as the putty can be formed in situ after 
mixing the components at the site of surgery.  
5) The final material will be moldable in nature and will have the potential to 
be applied at non-regular bone defects.  
The proposed solution encompasses the needs of patients as well as clinicians 
and would be an effort to bridge the gap between emerging technologies and 
clinical needs. The idea is novel in its approach as it provides a 
multifunctional approach to stop bone bleeding as well as augment bone 
repair. The novelty of the approach stems from the use of unique assembly of 
yolk shell particle composite with natural materials and a hierarchical 
organization, paving way for a spatio-temporal release of the entrapped 




particles and thrombin has not been used to provide hemostatic and 
osteoactive effects at the site of application. [12]. 
1.3 Objectives and Specific Aims 
The main objective of this project is to develop a moldable material that will 
aid in hemostasis and bone repair by virtue of hemostatic agent (thrombin), a 
sustained release of bone growth factors (BMP-2) and an osteoconductive 
element (hydroxyapatite). 
Specific aims: The main objective of this project can be achieved by 
completing the specific aims of the project. Each specific aim is divided into a 
few milestones that gauge their completion. 
Specific aim 1: To develop BMP-2 loaded ‘Yolk Shell Particles’ which 
provide a sustained release profile of BMP-2, maintain the functionality of the 
growth factors and demonstrate osteoactivity. 
Milestone 1: To optimize the synthesis parameters of the YSPs. 
Milestone 2: To ensure a sustained release of BMP-2. 
Milestone 3: To test the YSPs for cytotoxicity, functionality of the growth 
factors and the ability to induce osteogenic differentiation in cells. 
Specific aim 2: To assemble the YSPs and other components into a moldable 
putty that provides hemostasis, desirable mechanical properties and a 
sustained release profile of BMP-2.  
Milestone 1: To optimize the fabrication parameters for the putty like mixing 
ratios and mechanical properties; and measure the degradation profile of the 
putty in various media. 




Milestone 3: To monitor the hemostatic properties of the putty. 
Milestone 4: To evaluate the cytotoxicity of the putty and its effect on 
osteogenic differentiation of cells. 
1.4 Potential Application 
This product is intended to aid in overcoming the major shortcoming of 
uncertainty in achieving fusion in minimally invasive orthopedic surgeries.  
Currently, minimally invasive surgeries during orthopedic procedures use 
different material to achieve hemostasis and bone regeneration, which is 
inefficient. In this work, a novel moldable putty is developed which can 
simultaneously provide cues for hemostasis and bone repair in irregular 
shaped bone defects such as during spinal fusion. The product can assist 
surgeons to improve the bone regenerative process by controlling blood loss 
and delivering a concentration of bone growth factors at the same time to a 
localized area.  The patient is also likely to be benefitted by the advantages of 
minimally invasive surgery without the need to take additional bone grafts, 
resulting in less pain, less blood loss, faster recovery and shorter 
hospitalization. The techniques used in the development of the material can be 

























































Chapter-2: Literature Review 
 
2.1 Overview 
Lower back pain (LBP) is a commonly occurring disorder involving the 
muscles and bones of the back. In adults, the lifetime prevalence of LBP has 
been estimated as 85% [13]. It is reported that during any 6-month period, 
72% of adults in a given general population will report LBP and 11% will 
report disabling LBP [13]. Spinal fusion is a common therapeutic option for 
treatment of various spinal disorders. The most widely used methods to 
achieve spinal fusion include interbody fusion, wherein  a bone graft is placed 
between the vertebra in the area of the intervertebral disc, and posterio lateral 
fusion in which a posterior incision is used to place the bone graft (Figure 
2.1A) [14]. The two most important requirements of the procedure include 
achieving successful bone fusion and hemostasis at the site of surgery (Figure 
2.1B). Hemostasis is desirable immediately while the bone fusion takes time 






Figure 2.1: Techniques to achieve bone regeneration in Spinal fusion: A): Schematic showing 
interbody and posterio-lateral fusion strategy. Bone graft is placed between the vertebra in the area of 
the intervertebral disc in interbody fusion and a posterior incision is used to place the bone graft in 
Posterio Lateral Fusion. Successful bridge formation (functional bone regeneration and defect healing) 
B) can be seen indicating bone regeneration. (Courtesy NUS department of Orthopedic Surgery). 
     
Controlling intra operating bleeding, especially after decortication of the bone 
before the procedure, is extremely important in ensuring the success of the 
procedure. Traditional methods to control the bleeding include applying a mild 
suction [15], applying pressure through a sterile gauze or using materials such 
as bone wax [2] and water soluble hemostatic agents such as thrombin [16].  
Current treatment options for achieving successful bone fusion include the use 
of harvested bone grafts or using synthesized materials which can be natural in 
origin or ceramic and polymer based. Also, augmented methods using a 
growth factor and cell based approach in conjunction with the bone graft 
substitutes has also been reported. The current benchmark for treatment is the 
Successful 
Bridge 
formation   




use of autografts, with the bone being harvested from the ileum, rib, fibula or 
tibia [17].  
Currently the two problems i.e. attaining hemostasis and bone regeneration 
require intervention by at least two different agents as the methods to control 
bone bleeding do not aid in bone regeneration and the methods used for bone 
regeneration do not actively stop blood flow. This chapter on literature review 
explores the current state of the art in these procedures to achieve successful 
bone fusion and hemostasis.  
2.2 Issues Encountered during Minimally Invasive Orthopedic Surgeries 
As the name suggests, minimally invasive surgeries are less invasive than 
open surgeries and are becoming more and more popular. During a minimally 
invasive procedure for orthopedic surgeries such as spine fusion, the 
objectives to attain a successful procedure are two pronged; firstly it is 
important to ensure proper hemostasis and subsequently, adequate bone 
regeneration at the site. While current methods to combat blood loss include 
the use of physical pressure, bulk materials [2] and water soluble agents [16], 
the problem of achieving successful bone regeneration is generally solved by 










Figure 2.2: Techniques used to achieve hemostasis and bone regeneration in minimally invasive 








Hemostasis is a process which causes the bleeding process to stop by 
confining blood within a damaged blood vessel and is the first issue to be 
encountered during a surgical procedure [18]. Hemostatic agents are agents 
which promote hemostasis. Various agents/tissue sealants are used not only to 
minimize the blood loss during surgical procedures, but also to: 
 Improve visualization  
 Save operative time  
 Reduce or avoid transfusion  
 Prevent leakage of non-bloody fluids  
 Decrease post-operational drainage and infection  
 Decrease hospital length of stay [18]. 
Bone bleeding needs to be controlled during surgical procedures as any other 
living tissue, bone bleeds when cut or fractured. Excessive bleeding can also 
increase the risk of physiologic complications, and expose the patient to 
additional problems associated with blood transfusion [19]. 
The control in bleeding is required not only to prevent blood loss and 
hematoma formation for the patient, but also to ensure good visibility of the 
operating site for the surgeon.  
A fine line between bleeding and clotting needs to be maintained during 
surgery so that blood continues to flow to the tissues at the surgical site, but its 





Bone, being a tissue contains small vascular channels of the Haversian system 
in the cortical bone and a honeycomb network of vascular channels in the 
cancellous bone. Bone bleeding originates predominantly in the cancellous 
bone. A common practice during surgical procedures is to irrigate the bone to 
prevent heat formation and thermal injury to the bone [19]. Cauterization, a 
common practice used to control bleeding from soft tissues works by 
collapsing and sealing the blood vessels. If used to control bone bleeding, it 
would have to generate sufficient heat to create a coagulum to physically 
block vascular channels. This might cause thermal injury to neighboring bone 
negating any hemostatic benefit that the technique might offer [19]. So, other 
methods are used to attain hemostasis during surgical procedures involving 
bone. 
 
2.2.1.1 Techniques used to Attain Hemostasis, and their Limitations 
Currently, many products exist in the market which can arrest bleeding, such 
as Collagen, ORC (Oxidized Regenerated Cellulose),Gelatin ,Thrombin, 
Fibrin Sealants and Synthetic Sealants such as Bioglue , Floseal [18]. These 







Generally, the options available to surgeons today in arresting bleeding from 
bony surfaces at a site of fusion or bone reconstruction can be categorized into 
three main groups viz:  
1) Physical pressure with sterile gauze coupled with suction.  
This is always used when possible and proves to be sufficient depending on 
the location and surface area of the bleeding bone. This method is most suited 
for open surgeries where access to the site of bleeding is not an issue. 
2) Tamponade effect of bulk materials 
Bulk materials such as Bone Wax [2] are used by surgeons to stop blood flow 
by virtue of their physical properties. Also, materials such as tightly fitting 
block implants (e.g. BAK cages, autograft bone [2, 21]), and/or void fillers 
such as calcium phosphate derivatives, applied in the form of a paste or putty, 
have a tamponade effect on the void they are filling  and can stop blood flow. 





These are often sufficient but may not always be suitable in complicated 
procedures such as multi-segmental spinal fusion.   
Bone wax remains one of the most commonly used hemostatic agents.  It is 
formulated from beeswax, paraffin and isopropyl palmitate or Vaseline [2]. 
However, traditional bone wax is not degradable and is known to become a 
physical barrier obstructing new bone formation [1]. Therefore, bone wax is 
best used with caution for bone hemostasis and contra-indicated in spinal 
arthrodesis and other bone reconstructive or joint fusion procedures. Besides 
inhibition of osteogenesis, some of the other documented drawbacks of 
traditional bone wax that has become amplified with the advent of keyhole 
surgery include technical difficulties in application of bone wax as the firm 
pressure required for appropriate tamponade effect is difficult to achieve in 
deep seated bleeding. Because of this technical difficulty, bone wax could 
pose an increased risk as a foreign body particle. It could also detach more 
easily and embolise in circulation with potentially grave consequences [22]. 
Bone wax also lowers bacterial clearance, thus increasing risk of infection 
when attached to bone surfaces [22]. Additionally, granuloma formation has 
been reported in extreme cases of foreign body reactions [23].  
Moreover, the advent of more advanced strategies in bone healing involving 
growth factors and optimized scaffolds/carrier systems demands 
complementary advances in delivery and localization of these biological 
factors which are not met with these traditional bulk materials used to stop 






3) Water soluble hemostatic agents 





) [25] and gelatin/thrombin products 
(Floseal
®
) [26] have been used to control intra operative bleeding at the site of 
surgery. Some of these agents such as microfibrillar collagen, Hemostat 
(Colgel) and
 
oxidized cellulose (Surgicel) have been useful in arresting 
bleeding in many clinical scenarios particularly in high risk cardiac and 
hepatic surgeries [27]. However, many of the products do not possess any bulk 
properties and often do not actively enhance bone regeneration as they are 
neither osteoconductive nor osteoinductive. In some cases, some of the water 
soluble hemostatic agents have been reported to inhibit bone formation [28]. 
Besides, many of the products currently available lack immediacy effect and 
do not arrest bleeding as promptly as desirable. Furthermore, the observations 
of necrotizing granulomatous inflammation developing after bone hemostatic 
applications of products like microfibrillar collagen calls for caution in the 
application of this product particularly in bone hemostasis [29]. The handling 
properties of some of the water soluble products are also not suitable for use in 
bone bleeding. For example, oxidized regenerated cellulose (Surgicel, Oxycel) 
requires an absolutely dry operative field. While this is achievable in soft 
tissue bleeding, bleeding from trabecular bone would pose a real technical 







2.2.1.2 Unmet Need 
 
The bone healing process is naturally facilitated by the innate cycle of bone 
deposition, resorption and remodeling. This continuously occurring natural 
cycle of creation, destruction, and re-shaping of the osseous tissue is what 
facilitates the bone healing process [31]. Bone healing is characterized by 
three distinct but overlapping stages: 
1) Early inflammatory stage marked by hematoma formation and granulation. 
2) Repair stage in which cartilage and callus replace hematoma.  
3) Late remodeling stage marked by the bone regaining its shape, 
improvement in circulation and mechanical strength [31].  
Inflammation and revascularization occurs within the first 1 to 2 weeks are a 
period in which inflammatory cells and fibroblasts infiltrate the bone resulting 
in the formation of granulation tissue, ingrowth of vascular tissue, and 
migration of  mesenchymal cells [19, 32]. The mesenchymal cells then 
differentiate into osteoblasts and osteoclasts. Osteoblasts secrete osteoid, 
which is the unmineralized organic matrix and subsequently undergoes 
mineralization, giving the bone its strength and rigidity. Osteoblasts also play 
a role in the  activation of bone resorption by osteoclasts [32]. It has been 
shown that the application of a thin layer of bone wax on a cut surface of the 
bone interferes with bone healing even if bone wax has been applied and then 






Attaining hemostasis in a controlled and desirable manner is thus a key 
parameter in successful implant and subsequent success of a bone graft. Since 
agents such as Bone wax not only compromise the bone’s ability to heal by 
increasing the risk of osteomyelitis [33], but also interfere with healing 
directly by disrupting the regenerative processes necessary to achieve an 
osseous fusion after surgery; and excessive bleeding from bone surfaces has 
been known to impede failure of grafts (Figure 2.4, 2.5, Table 2.1),  there is a 
need for a viable alternative to current strategies that combines the 
effectiveness of soluble hemostatic agents such as thrombin, and couples it 
with the advantages of using bulk materials and eliminates the inflammatory 
nature of currently used agents such as bone wax. Although several water 
soluble alternatives to traditional bone wax have been introduced [2], they 
have been shown to be adequate in a number of clinical scenarios. Also, poor 
handling properties and lack of immediate hemostatic effect implies that 
traditional bone wax continues to be widely used when not contra-indicated 
and in spite its known drawbacks. Current methods, even though fairly 
proficient in stopping the blood flow do not help to promote bone regeneration 
and stay inert at best. While materials such as calcium phosphate cements 
promote bone regeneration, they do not promote hemostasis in an active 
manner. Hence, for the purpose of orthopedic bone reconstructive surgeries, 
there is a need for a hemostatic agent that not only actively promotes 








Figure 2.4: Problem of profuse intra-operative bleeding: Blood oozing (circle) from decorticated end 
plate even after extensive manual pressure (packed with gauze) A). Bleeding continues after insertion of 
implant loaded with collagen sponges and rhBMP-2 B). Notice significant bleeding upon insertion of 




Figure 2.5: Failed spinal interbody fusion: as observed A, B) and partial fusion C) after insertion of 
relatively low dose rhBMP-2 and PCL-TCP into L2/3 and L4/5. Notice failure of through bone growth at 
site of implant (circle) and excessive bone formed at adjacent sites  D). The location of the excessive 
bone corresponds to the site of accumulation of the oozing blood as shown in Fig 2.4 above. (Image 








Table 2.1: Summary of methods used to attain hemostasis and their known disadvantages. 
 
2.2.2 Bone Regeneration 
For achieving successful bone regeneration, it is important to attain a 
successful integration of the bone substitute used and the host bone. To 
achieve a successful bone fusion with desired mechanical and biochemical 
properties, it is desired that the material used for bone fusion should have the 
following properties [3]: 
a) Mechanical Strength and Homogeneity. 
The material used for the procedure should be able to provide adequate 
mechanical support at the host site. This is important to maintain homogeneity 
TREATMENT OPTIONS PRIMARY DISADVANTAGES 
 





Tamponade effect of Bulk Materials 
 Unsuitable for deep seated bleeding. 
 Inability to carry growth factors. 
 Foreign body reaction and lowering of 
bacterial clearance. 
 Granuloma formation. 
 
Water soluble hemostatic agents 
 Inadequate handling properties. 
 Lack of immediacy effect (inability to 
arrest bleeding as promptly as 
desirable). 





of the structure and to allow the newly formed bone to match the structural 
and dimensional properties of the erstwhile bone.  
b) Osteoactivity 
Secondly, it should be osteoactive, that is, it must effect, promote and or 
facilitate formation of new bone at the implant site. Osteoactivity includes 
osteoinductivity and osteoconductivity. While osteoinduction involves the 
stimulation of osteoprogenitor cells to differentiate into osteoblasts hence 
beginning new bone formation, osteoinductive (also termed osteogenic) 
materials achieve the purpose of bone regeneration  by recruiting 
mesenchymal cells from the vicinity of the graft/implant [3]. Osteoconductive 
materials serve as a scaffold for new bone growth that is perpetuated by the 
native bone materials and allow ingrowth of vessels and osteoprogenitor cells 
from the recipient bed into the implant or graft [34]. 
c) Biocompatibility and comfort 
Biocompatibility and comfort are of paramount importance in achieving a 
successful bone graft procedure in the long run. It is desired that the implant 
should not cause pain or discomfort, fracture, excessive bleeding, foreign body 
response, deformity, or transmission of disease [3]. Another issue to take care 
of is the disparity in resorption rate of the graft and native bone, failing to 






2.2.2.1 Techniques used to Achieve Bone Regeneration, and their 
Limitations 
The methods to achieve bone fusion can be broadly classified into the use of 
bone graft substitutes and the use of supplements used to enhance bone 
regeneration (Figure 2.2). Bone graft substitutes include harvested bone and 
synthetic materials. Harvested bone includes bone harvested from the same 
patient or cadavers and synthetic materials include the use of polymers, 
ceramics and naturally found materials such as corals and sponge skeletons. 
With the recent advent of the discovery of stem cell based methods and 
identification of various growth factors that promote osteoactivity, augmented 
approaches are also being taken to supplement the traditional methods with 
growth factors and/or cells. 
2.2.2.1.1 Bone Substitutes 
Bone substitutes include materials which replace/augment the injured or 
missing bone at the site of surgery. Here, we classify them as follows: 
2.2.2.1.1.1 Non Moldable Bone Substitutes 
These include materials which are manufactured or harvested in a specified 
shape and do not set/transform physically or chemically upon implantation. 
They mainly include: 
Autografts 
Autografts are the current gold standards for bone replacement and are 
traditionally used  for  treating  non-unions/delayed unions, filling bone 





spinal fusion etc. (Figure 2.6 A) [3, 35]. The main reason for their use is the 
fact that they offer the best histocompatibility and osteoactivity and the least 
immunological rejection (Figure 2.6 D) [3, 36]. Although bone can be 
harvested from both cortical as well as cancellous bone sites, autologous 
cancellous bone grafts have been considered more osteogenic as compared to 
their cortical counterparts, owing to their porosity which allows the diffusion 
of nutrients and revascularization by micro-anastomosis of its circulating 
vessels [3, 36]. Common harvesting sites for autografts grafts include ilium, 
ribs, fibula and tibia with each site offering a different osteogenic potential 
[17]. 
As compared to cancellous bone, cortical bone demonstrates lesser osteogenic 
potential but higher strength, and is considered third order bone [3].  
Although autografts have the best possible biocompatibility among all known 
methods of achieving bone fusion, they present significant disadvantages as 
well. First and foremost is their limited supply. Secondly, the procedure to 
carry out bone harvesting is very complex and includes issue such as donor 
site morbidity and may involve massive blood sepsis and pain. Further, post-
surgical complications such as pelvic instability, fatigue fracture and 
heterotopic bone formation have also been reported [17]. 
Allografts 
Allografts include harvested bone grafts from different individual but of the 
same genotype (Figure 2.6 B). Allograft bone has osteoconductive (they 
release bone morphogenetic proteins) and osteoconductive properties but lack 
osteogenic properties as they lack viable cells. Although, this circumvents the 





occur at a slower rate [3]. They have also shown to register a higher resorption 
rate, greater immunogenic response, and less revascularization of the graft, as 
compared to autografts [37]. 
It has been shown that freeze drying lowers the antigenicity of allografts, but it 
is known to alter the physical properties of graft material, resulting in a 
decrease in new bone formation [3]. This procedure is relatively unknown and 
the optimal temperature and conditions are not very well understood creating 
reasonable doubt regarding their effectiveness in decreasing the antigenicity. 
Also, using allogeneic bone requires proper harvesting, proper storage and 
bone banking. The sterile conditions required to procure the bone makes it a 
lengthy and tedious procedure [38]. 
Other allogeneic materials, like autolyzed antigen-extracted allogeneic (AAA) 
bone have also been investigated. This process decreases the immunogenicity 
but tends to increase the rate of resorption [39]. 
The possibilities of viral contamination of the graft materials and the 
concurrent risk of transmission of the virus to the recipient has caused a 
decline in the use of allogeneic bone henceforth paving a need for better bone 
substitutes not prone to the disadvantages discussed earlier.   
Demineralized bone matrix (DBM) is an allograft bone from which the 
inorganic mineral is removed leaving behind the organic collagen matrix 
(Figure 2.6 C). DBM has been shown to have an osteoconductive and 
osteoinductive potential [40-43] but is not an adequate candidate for providing 
the required structural strength. As the antigenic surface structure of the bone 
is destroyed during mineralization, it does not evoke any appreciable local 





reported in instances of inducing bone formation in scenarios involving filling 
the defects caused by bone cysts and cavities [45-47] , Cranio-maxillofacial 
reconstruction [48], bridging of large bone defects and repairing high risk 
fracture [49]. Known disadvantages of DMB include the potential to transmit 
HIV and inter sample variation in properties and potency [47].  
 
 
Figure 2.6: Autografts and Allografts. A) Autograft being harvested during surgery[50]. B) Allograft 
stored under sterile conditions [51]. C) Demineralized Bone Matrix [52] and D)Section of an 8-mm 
trephine defect in the rabbit cranium filled with autogenous bone chips at 2 weeks. Bridging of the defect 
and new trabecular bone at the surface of the particles can be observed [3]. 
 
Xenografts 
Although not as commonly used as autografts and allografts, Xenografts or 
grafts shared between different species, also provide a bone replacement 
option and through different processing techniques, have shown 
biocompatibility [53]. Currently, the main sources of Xenografts are bovine 
bone [54], porcine bone [55] and corals [56]. Xenografts are osteoconductive 
and are readily available  but have shown to cause disease transmission in 
some cases [57].  
 







Synthetic Bone Graft Substitutes 
Due to the limited availability of harvested bone materials for bone fusion 
there has been an increase in the use of synthetic materials for the purpose. 
The major synthetic materials used as bone graft substitutes include polymers, 




Figure 2.7: Synthetic bone graft substitutes: A-D): Fibrin based material being used as a bone graft.  
Black arrows show the placement of the material and the white arrows show the advancement of the 
bone front.[58] E) Collagen based materials commercially available [59].F) Pro-Osteone HA [60] F-G) 
PLA based scaffolds for osteoconduction [61]. 
 
Polymers are repeatedly finding more use as bone graft substitutes owing to 
their different and tunable physical, mechanical, and chemical properties. The 
polymers used today can be loosely divided into natural polymers and 
synthetic polymers.  





and agarose [62-66], many of which are components of extracellular matrix. 
They are biocompatible, bioresorbable and can be formulated into many 
configurations with variable residence time using enzymatic treatment and 
chemical cross-linking.  
Collagen, which is the major non-mineral component of bone, can be made 
into formulations including gelatin, demineralized bone matrix (DBM), and 
fibrillar collagen. 
Hyaluronans, also present in extracellular matrix, can be formulated into gels, 
sponges or pads [67]. Other naturally occurring polymers such as chitosan, 
alginate and agarose can be formulated as hydrogels and in some cases 
sponges or pads or beads in case of agarose.  
Among the synthetic polymer based bone graft substitutes, Poly (a-hydroxy 
acid) polymers such as polylactide, polyglycolide and their copolymers (poly 
(D, L-lactide-co-glycolide) (PLGA) are the most commonly used synthetic 
polymers. Additional Polyanhydrides, Polyphosphazenes, Polypropylene 
fumarate, polyethylene glycol- PLA [68], poloxamers [34], and polyphosphate 
polymers [69] have also been used (Figure 2.7). The major advantage of using 
synthetic polymers is their design flexibility and elimination of disease 
transmission. Synthetic polymers can be processed into highly porous three-
dimensional scaffolds, linearly oriented scaffolds, fibers, sheets, blocks or 
microspheres. However, their major drawbacks include immunogenic 
rejection, inflammatory responses and formation of toxic degradation products 
[17]. 
Ceramics such as Hydroxyapatite, or HA (Ca10(PO4)6(OH)2,) which is the 





produced as a biocompatible ceramic. It is a highly crystalline form of calcium 
phosphate, and hydroxyapatite based materials have been used regularly in 
orthopedic applications due to their osteoconductive potential and excellent 
biocompatibility [70-72]. For instance, in the case of posterio-lateral lumbar 
inter-transverse process spine fusion (PLF), the use of hydroxyapatite has 
shown promising results due to its  interconnected porous structure thereby 
producing a fusion mass with high cellular viability [73, 74]. Hydroxyapatite 
has also been used in combination with bone grafts as demonstrated by  Toth 
et al [75], who reported that HA when mixed with autograft in the ratio of 70 
(ceramic): 30 (autograft) was effective for anterior cervical interbody fusion. 
But, as a stand-alone bone substitute, HA has not shown very promising 
results  [76]. 
Hydroxyapatite is also an excellent carrier of osteoinductive growth factors 
and osteogenic cell populations. As there has been an increasing demand of 
doped bio-ceramic materials to enhance their mechanical and biological   
properties  [77-79] , doped HA with manganese and/or zinc as bone substitute 
have been tried and resulted in faster resorption kinetics [80]. Also, HA in the 
form of plasma spraying has been used as a coating agent to alleviate 
commonly encountered fixation problems in materials such as PMMA [81]. In 
other instances, Hydroxyapatite-coated pins have been shown to enhance 
among varied fixation scenarios and bone types used by reducing the rate of 
infection and loosening during external fixation [82, 83]. 
In vivo implantations of  HA have shown osteoconduction , a lack of local and 
systemic toxicity, no inflammation, and no foreign body response [84] and 





intervening fibrous layer [84]. Although HA demonstrates mechanical 
properties similar to cortical bone [3], its highly brittle nature remains a 
roadblock in its use as a hard tissue prosthetic. Other discouraging 
characteristics of HA include its low solubility within the body and 
mechanical properties mismatch from surrounding tissue and bone [79]. 
Metals such as Titanium are also used as bone graft substitutes either in 
isolation or in conjunction with other bone graft materials to provide structural 
support [53]. However, they are not osteoactive and need to be treated with a 
bioactive component before application. 
 
2.2.2.1.1.2 Moldable Bone Substitutes 
As the name suggests, these materials are moldable in nature (Figure 2.8) and 
set or harden upon implantation. They mainly include ceramics like calcium 
phosphates and sulfates which are inorganic materials prepared by high 
temperature treatment followed by subsequent cooling. Since the mineral 
phase of the bone, which is also the major component of the bone’s total 
weight, is also inorganic in nature, ceramic based materials have also been 











Calcium Phosphates and Sulfate Cements 
Calcium phosphate cements are a group of materials which include a mixture 
of powders “which, upon mixing with water or an aqueous solution to a paste, 
reacts around room or body temperature by the formation of a precipitate 
containing crystals of one or more calcium phosphates and sets by the 
entanglement of the crystals of that precipitate” [85]. 
Calcium phosphates and sulfates also find repeated use in orthopedic 
applications owing to their innate similarity to the natural composition of the 
bone. Some common examples are Tri Calcium Phosphates (TCP), calcium 
phosphate and calcium sulfate. 
TCP is a group of bio-absorbable and biocompatible materials, similar to 
hydroxyapatite, with chemical composition and crystallinity comparable with 
those of the mineral phase of bone and is also widely used in orthopedic and 
dental applications. TCPs have a small particle size and have interconnected 
sponge like micro porosity which improves their osteoconductive properties 
and promotes timely resorption which normally accompanies the natural 
remodeling process of the bone [70, 72, 86] . However, its rate of 
biodegradation is higher as compared to that of HA [87]. 
Calcium phosphate based ceramics have been in use for a long time and are 
regarded as bioactive bone substitutes. The most common form of their 
application is in the form of a paste or injectable cement. This makes them 
moldable and adaptable to bone defects. Various phosphates of calcium are 





for their popularity is their ability to form HA in situ upon contact with the 
physiological fluid after implantation [3]. It has also been shown that contrary 
to prior belief, calcium phosphate cements directly initiate osteogenesis [88].  
Like their phosphate counterparts, calcium sulfate graft materials have also 
been used in similar applications and a calcium sulfate based graft material  
with a patented crystalline structure, described as an alpha-hemihydrate, which  
acts primarily as osteoconductive bone-void filler that completely resorbs as 
newly formed bone remodels and restores anatomic features and structural 
properties has been reported [3]. Calcium sulfate graft materials have been 
used for filling of cysts, bone cavities [89], benign bone lesions [90] and 
segmental bone defects; expansion of grafts used for spinal fusion; and filling 
of bone graft harvest sites [91]. They have been known to be biocompatible, 
bioactive and resorbable [92].  
Despite showing potential, the main drawback in using CPC and sulfate 
materials is the close proximity to the host bone which is required to achieve 
osteoconduction. Even when this is achieved, new bone growth is often 
strictly limited because these materials are not osteoinductive in nature. CPC 
also suffers from its inherent lack of microporosity for tissue invasion [88] and 
poor injectability [93]. Also, significant loss of its mechanical properties has 
been reported upon its degradation therefore making it unsuitable for load 
bearing applications. 
Hydroxyapatite has also been formulated into a moldable materials such  as a 
ready-to-use paste in a syringe, available under the name Ostim™ (Heraeus 
Kulzer, Hanau, Germany) (NHA) and synthetic nanocrystalline HA (NHA) 







Bio-active glass ceramics or Bioglass, are a group of surface reactive glass-
ceramic biomaterials composed mainly of silica, sodium oxide, calcium oxide 
and phosphates and were first developed by Hench et al [94]. Bioglass 
particles tend to form cohesive mass when they come in contact with body 
fluids and can be easily manipulated and packed into bone defects (Figure 
2.8B  [53]). They are biocompatible, osteoconductive and bond to bone 
without an intervening fibrous connective tissue interface [95, 96]. They have 
been widely used for filling bone defects [71, 97, 98], alone and in 
combination with autogenous and allogeneic cancellous bone graft [99]. 
Bioactive glass ceramics have tunable properties as their behavior is 
dependent on the composition of the glass [100, 101], the surrounding pH, the 
temperature, and the surface layers on the glass [102, 103]. They have surface 
porosity that provides a scaffold on which newly-formed bone can be 
deposited after vascular in growth and osteoblast differentiation and is also 
beneficial for initiating and maintaining resorption and bioactivity [104].  
Bioactive glasses show little or no inflammatory responses in the surrounding 
tissue in histological in vivo studies and have been shown to be completely 
reabsorbed 6 months post implant [105]. Bioactive glasses have also been used 
for tympanoplastic reconstruction [106], as filling material in benign tumor 










Figure 2.8: Moldable materials as bone graft substitutes: A) Moldable calcium phosphate based 
material (top and bottom) [51].B) An injectable material made of bioactive glass [108]and C) Section of 
trephine defect in the rabbit cranium filled with HA demonstrating osteoconduction and lack of 
significant resorption [17].  
 
2.2.2.1.2 Augmented Methods for Bone Regeneration 
Due to the shortcomings of the currently used methods for bone regeneration, 
and with the advent of technology; augmented strategies employing the use of 
a combination of methods in conjunction with the use of bone substitutes are 
steadily becoming more and more popular in order to improve upon the 
osteoactivity and biocompatibility of the traditionally used bone graft 
substitutes. 
2.2.2.1.2.1 Cell Based Approach 
Cell based strategies augment the current bone graft substitutes in improving 
their osteogenic properties and stem cells, especially mesenchymal stem cells, 
are widely used for this purpose.  Stem cells are undifferentiated cells capable 
of producing any identical daughter cells under appropriate stimuli (Figure 





embryonic stem cells. Somatic stem cells include hematopoietic stem cells, 
bone marrow stromal (Mesenchymal) stem cells (MSC) [109, 111] neural 
stem cells [112], dermal (Keratinocytes) stem cells [113], stem cells from fetal 
cord blood [114] and several others (Figure 2.11). Most commonly derived 
stem cells are those derived from the bone marrow which yields two types, the 
hematopoietic stem cells which gives rise to the entire blood cell lineage and 
the mesenchymal stem cells which give rise to various connective tissues such 
as bone and adipose tissues. Mesenchymal stem cells are currently being used 
for the repair and regeneration of bone, cartilage, muscle, tendon and ligament 
[115]. Cultured mesenchymal stem cells (MSCs) in combination with porous 
ceramics have shown osteogenic potential when implanted into rat [115, 116] 
or canine segmental bone defects . Cultured MSCs have also been successfully 
implanted into massive osteochondral defects in the medial condyle of the 
distal femur of young adult rabbits [117, 118] in an attempt to provide 
regeneration of both cartilage and bone. 
Though they sound promising, stem cells require stimulating factors to 
facilitate differentiation and the means of delivering factors to stimulate stem 
cells in vivo to initiate a process leading to regeneration has long been sought 
and restricted by problems of dosage, lack of full activity of recombinant 
factors and the inability to sustain the presence of the factor for an appropriate 
length of time [3].  
Despite the challenges of isolating, expanding and defining stem cell 
populations, they hold tremendous promise for tissue regeneration at a 





thorough research is needed to characterize graft versus host stem cells 
immune interactions and to identify mechanisms enabling the delivery or 
homing of the stem cells to the site of interest in clinical context. 
 
Figure 2.9: Mesenchymal stem cells and their differentiation cues into different cell types. [119]. 
2.2.2.1.2.2 Gene Therapy 
Gene therapy involves the transfer of genetic information to cells and utilizing 
the innate ability of the gene to synthesize its encoded protein in the target cell 
[17]. This approach has been used sporadically in conjunction with other bone 
graft substitute methods to accelerate bone formation in vivo. Strategies to 
introduce the gene include a  direct introduction to specific anatomic site (in-
vivo technique) or harvesting specific cells followed by expansion, genetic 
manipulation and tissue culture followed by subsequent re-implantation (ex-
vivo technique). Where the direct method is less technically challenging, the 
indirect gene delivery is safer as the gene manipulation takes place under 
controlled conditions outside the organism [17]. Viral and non-viral vectors 





vectors encoded for the gene of bone morphogenetic protein-7 have been 
successfully used in conjunction with polymer scaffold grafts implanted into 
osteochondral defects in rabbit knees [120]. In some case, virus based gene 
therapy strategies for augmenting bone graft materials are however prone to 
infection, thereby compromising the efficiency of their gene delivery [121, 
122]. Another gene therapy method used for promoting bone regeneration is 
the use of RNA interference. RNA interference (RNAi) is a naturally 
occurring cellular process that regulates gene expression by  sequence-directed 
gene silencing and can be used to target any disease-associated pathogenic 
gene of interest [123, 124]. Accordingly, RNAi-based therapies targeting those 
genes negatively regulating bone formation have been shown to facilitate 
translational therapy for treating diseases marked by impaired bone formation 
[123, 125]. However, an area of major concern is the large therapeutic doses 
of systemically administered RNA (siRNA) that would be needed to stimulate 
sufficient bone formation. This may carry a high risk for adverse effects in 
non-skeletal tissues [126].  
 
2.2.2.1.2.3 Use of Growth Factors and other augments 
To facilitate osteoinduction and osteogenic differentiation when using a bone 
graft substitute or otherwise, a myriad of agents have been used. They majorly 
consist of soluble protein factors like tumor necrosis factor α (TNF- α) family 
[127], the transforming growth factor β (TGF- β) super family [127], 
angiogenic factors, bone morphogenetic proteins (BMPs), dexamethasone 





[128]. The BMPs are multifunctional growth factors that are part of the 
transforming growth factor beta protein family and out of all factors used for 
bone regeneration,  BMP-2 has been shown to be one of the most potent 
members of the BMP family for the induction of bone formation in vivo [6, 
129, 130].  
The growth factor bFGF has also been shown to augment the osteoinductive 
potential of BMP-2. Combinations of BMP-2 and bFGF demonstrated 
synergistic effects in osteogenic differentiation of MSCs in vitro and enhanced 
bone formation in vivo [128, 131, 132] . 
In addition to the protein growth factors, the active form of Vit-D3 has also 
been shown to demonstrate an important role in skeletal homeostasis by 
displaying anabolic effects on osteoblasts and causing an increased bone 
formation [128, 133]. In vitro studies have shown that treatment of hMSCs 
with Vit-D3 induced expression of both early and late stage. 
The most potent of all growth factors used to stimulate bone formation, Bone 
morphogenetic proteins (BMPs) are a group of growth factors also known 
as cytokines and play an important role in signaling pathological processes by 
interacting with specific receptors on the cell surface, referred to as bone 
morphogenetic protein receptors (BMPRs) [134]. 
The signaling pathways involving BMPs and BMPRs are important in the 
development of the heart, central nervous system, cartilage as well as post-
natal bone development; due to which members of the BMP family are 





Specifically, BMP-2 has been shown to be one of the most potent members of 
the BMP family for the induction of bone formation in vivo [6, 129, 130]. This 
has been validated by the fact that in several types of cell culture such as 
embryonic stem cell [7], human mesenchymal stromal cell [136] and C2C12 
myoblast [137], BMP-2 has been shown to increase the expression of alkaline 
phosphatase (ALP), osteopontin, Runt-related transcription factor 
2,osteocalcin, and collagen type I. Accelerated closed fracture healing in rats 
[11, 138], fracture healing in rabbits [139], osteotomy healing in rabbits [140] 
and Achilles tendon healing in rabbits [141] has been reported following 
treatment with bone morphogenetic proteins (BMPs) delivered in formulation 
buffer. 
BMP-2 and BMP-7 have also received Food and Drug Administration (FDA) 
approval for human clinical uses.  
Given the importance of BMPs, constant research is being done to find the 
optimal way of delivering BMPs to the intended site of application. Factors to 
consider here are to maintain the biofunctionality of BMPs over the intended 
time as BMPs have been known to lose their bioactivity over a short time, and  
not exhibit the required efficacy in bone regeneration in vivo [66]. 
It has been established that the carrier for BMPs should have the following 
characteristics [66]: 
1.) Carriers for BMPs should increase retention of these factors at orthopedic 
treatment sites for a sufficient period of time to allow regenerative tissue 






2.) Carriers can also serve as a matrix for cell infiltration while maintaining a 
space or volume in which repair tissue formation can occur. 
3.) Carriers have to be biocompatible and are often required to be 
bioresorbable.  
4.) Carriers also have to be easily, and cost-effectively, manufactured for 
large-scale production. 
5.) Carriers should have appropriate storage conditions and stability.  
 
BMP-2 delivery strategies may be viewed in terms of hierarchical organization 
and configuration of their carriers.  
 
Point or Depot Delivery of BMP-2 
The most common methods of delivery of BMP-2 remain confined to the use 
of simple depot delivery systems which mainly includes nanoparticles, 
microspheres, beads and minipellets [66]. Most commonly used depot delivery 
strategies include polymeric nanoparticles, commonly made of PLGA, PLA, 
PCL and PMMA and they release the protein into the extracellular matrix as 
they degrade. They have shown promising results (Figure 2.10, [142]), but are 
limited by problems such as burst release of BMP-2 which has known to cause 
ectopic bone formation  [143]. 
As a way to impart multi-functionality to these depot delivery systems, 
microcapsules are used which pave way to incorporate an array of cargoes as 
the delivery through them can be controlled via the permeability of the capsule 





from the surrounding environment but release them in a controlled manner 
[144]. 
Increasing the complexity of nanoparticles and microcapsules, recently, Yolk 
shell particles have found way in the field of drug delivery and detection. They 
possess a distinctive “core-void-shell” configuration [145] (Figure 2.11).With 
the unique properties of movable cores, interstitial hollow spaces, and the 
functionality of shells, yolk shell structures have great potential for application 
in various fields, such as nanoreactors [145], biomedicine [146]  and 
photocatalysis [147]. 
Yolk/shell particles combine the properties of each of their components and 
hence can be tailored to a wide degree which results in some novel and diverse 
holistic properties. For example, the shells of the yolk/shell particles, just like 
a protective layer, could prevent core particles being released from the shells 
but allow small molecules to permeate to the core particles through the shells, 
and the hollow space between core particles and shells could also provide 







Figure 2.10: Polymer based delivery of BMP-2: A-B) BMP-2 loaded PLGA microspheres. C) Alizarin 
staining showing calcium deposition sites in myoblasts when treated with BMP-2 Loaded polymeric 
particles. D) BMP-2 loaded polymeric particles embedded in a Poly Capro-Lactone scaffold [142]. 
 
 
Figure 2.11: SiO2-SiO2 yolk shell nanoparticles: These images under varying magnification show the 
hierarchical structure of these particles[147]. 
 
BMP-2 Delivery Systems Recruiting Components of ECM 
As the depot delivery systems like nanoparticles and capsules do not serve any 
matrix functions [66], The next order of complexity are carriers that partially 
reconstitute properties of the extracellular matrix (ECM). These include 





and agarose [62-66], and calcium orthophosphates. By providing a release of 
BMP-2 and incorporating the components of the extracellular matrix, these 
strategies use the osteoinductive nature of the bone morphogenetic proteins 
and the osteoconductive influence of the natural polymers and 
orthophosphates. The major factor to consider here is to maintain functionality 
of the growth factor and ensure a sustained release is maintained over the 
desired period. 
Another issue associated with the use of growth factors to augment bone 
regeneration is that blood oozing from bony surfaces could result in washing 
away of growth factors delivered on carriers. This has a potential risk of 
failure of bone healing or psuedoarthrosis as well as excessive bone formation 
at adjacent or ectopic sites. Although the use of excessively large doses of 
growth factors such as BMP-2 is commonly advocated in order to compensate 
for such wastage, there are some caveats. Unique complications such as 
delayed osteolysis, excessive tissue swelling and hematoma that could 
necessitate a second surgery, have been associated with the supraphysiological 
doses of this highly potent growth factor [143]. The large doses could also 
have serious cost implications on patients. 
2.2.2.2 Unmet Need 
Upon study of the current methods used for bone regeneration, it can be seen 
that there is a need for a material than can provide a sustained release of 
osteoinductive factors such as BMP-2, paves way for osteoconduction by 
incorporating components of the extracellular matrix and possess adequate 





moldable, along with provision of the mentioned characteristics would be an 
added advantage as it would improve the handling property of the material. 
2.3. Concluding Remarks 
In the review of the materials used for hemostasis and bone regeneration 
during orthopedic surgeries, it can be seen that either is faced with some 
disadvantages.  
While hemostatic materials such as bone wax, though potent in controlling 
intra-operative bleeding, have been found to inhibit bone growth and cause 
inflammatory reactions, soluble hemostatic factors like thrombin face a 
problem of limited retention  at the site of surgery. Also, it should be noted 
that these methods do not aid in bone regeneration and their sole purpose is to 
control the bone bleeding. 
As far as achieving successful bone regeneration is concerned, to combat the 
issue of limited supply of autografts, bone substitutes augmented by growth 
factors are the most popular options. However, there is a need to control burst 
release of this growth factor associated with depot delivery systems such as 
polymeric nanoparticles, and to maintain the functionality of the growth 
factors during the course of synthesis of the delivery systems. Also, traditional 
bone graft substitutes do not actively cause hemostasis. This means that a 
surgical intervention is required at two stages; first to implant the graft or 






Hence, there is a need for material that offers a dual function of actively 
arresting bleeding from bony sources, and causing successful bone 
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Chapter-3: Silk Fibroin Based Yolk Shell Particles for Sustained Release 
of BMP-2 
 
3.1 Introduction  
As mentioned in Chapter 2, current methods of achieving bone repair through 
augmented bone graft substitutes are hampered due to the need of 
supraphysiological loading of growth factors. BMP-2 has been shown to be 
one of the most potent members of the BMP family for the induction of bone 
formation in vivo [5, 6, 130]. In order to maintain the potency and maximize 
the effects of BMPs, there is a need to maintain their biofunctionality over the 
intended time as they have been known to lose their bioactivity over a short 
time, and not exhibit the required efficacy in bone regeneration in vivo [66]. 
Intuitively, the simplest mode of delivery of BMPs would be to administer 
them in solution, but this may cause the BMPs to be washed away. It has been 
established that the carrier for BMPs should increase retention of these factors 
at orthopedic treatment sites for a sufficient period of time to allow 
regenerative tissue forming cells to migrate to the area of injury and to 
proliferate and differentiate. Carriers have to be biocompatible and 
bioresorbable and at the same time possess the ability to be easily, and cost-
effectively, manufactured for large-scale production [66].  
Natural polymers like collagen, hyaluronans, fibrin, chitosan, silk, alginate, 
and agarose [62-66], many of which are components of extracellular matrix, 
have been used for BMP-2 delivery. They are biocompatible, bioresorbable 
and can be formulated into many configurations with variable residence time 




Synthetic polymers like Poly(α-hydroxy acid) polymers such as polylactide, 
polyglycolide and their copolymers (poly(D,L-lactide-co-glycolide) (PLGA) 
are the most commonly used synthetic polymers to deliver BMPs. Additional 
Polyanhydrides, Polyphosphazenes, Polypropylene fumarate, polyethylene 
glycol- PLA [68], poloxamers [148], and polyphosphate polymers [69] have 
also found  use for BMP delivery. 
Although synthetic polymers offer excellent design flexibility, naturally 
occurring polymers such as chitosan, alginate, silk and agarose can also be 
formulated into various configurations like sponges, pads or beads [66]. Silk 
Fibroin proteins (SF) from Bombyx mori, have been used as a biomaterial for 
tissue engineering and drug delivery [149-154]. Silk proteins are amphiphilic 
in nature and [117, 149-154] comprise of large domains of hydrophobic amino 
acids, separated by relatively short and more hydrophilic regions. The 
hydrophobic domains of the protein have the tendency of organizing into 
protein crystals, beta sheets, which form physical crosslinks to stabilize silk 
structures [155]. Silk fibroin (SF) has been shown to exhibit superior 
mechanical properties as compared to other natural degradable materials. It 
also exhibits tunable degradation rates (ranging from weeks to months) in vivo 
due to control of crystallinity, excellent biocompatibility with low 
inflammatory and immunogenic response and processing options to form 
films, fibers, gels, sponges and microspheres. In the area of drug delivery, 
especially protein drugs, silk materials exhibit high encapsulation efficiency 
and controllable drug release kinetics [150, 152]. 
Many methods to prepare drug loaded micro and nano particles have been 




displacement, phase separation, self-assembly, rapid expansion of supercritical 
fluid solution, and spray drying [156]. Each method has pros and cons, so 
selection of an appropriate method is important in fabricating micro and nano 
particles for drug delivery applications.  
It is important to maintain the biofunctionality of the encapsulated proteins, 
hence a method was devised to bypass the use of organic solvents in the 
synthesis of silk based particles and produce particles with low polydispersity. 
Commonly used solvents for emulsion-solvent extractions include xylene, 
toluene, dichloromethane and acetone [144]. Here, we use a completely 
natural oil phase in the form of corn oil to eliminate the harsh effects of 
organic solvents on the delicate protein structure of BMP-2. 
This chapter describes the development of novel yolk-shell particles made of a 
natural polymer, silk fibroin, which are easy to make, retain the functionality 
of the growth factors during and post synthesis and can provide a sustained 
release of BMP-2 over a prolonged period of time. These particles possess a 
unique core-void-shell configuration also known as yolk–shell configuration. 
Core–shell and hollow structures have been traditionally used for controlled 
release of encapsulated proteins [145] . Yolk shell particles are a special class 
of core-shelled structures with a distinctive “core-void-shell” configuration 
and have attracted significant attention in recent times  [145]. They combine 
the properties of each of their components and hence can be tailored to a wide 
degree which results in some novel and diverse holistic properties. The idea 
here is to use the shells of the yolk-shell particles like a protective layer to 
prevent burst release of growth factors on the core particles and protect the 




We propose novel silk fibroin based yolk shell particles which combine the 
principles of self-assembly and microencapsulation, thereby eliminating the 
need of harsh chemical processes such as calcination or etching. These 
particles not only provide a template for time dependent release of growth 
factors, but also shield the encapsulated proteins from unfavorable 
environments during synthesis and release.  
3.2 Materials and Methods 
3.2.1 Reagents, Materials and Equipment 
Model drug Fluorescein isothiocyanate-Bovine Serum Albumin (FITC–BSA) 
(66,000 Da), FITC-Dextran, Rhodamine isothiocyanate (RITC), calcium 
chloride, tween and Polyvinyl alcohol (PVA) (85000–124000 Da) were 
purchased from Sigma–Aldrich. BMP-2 was purchased from Medtronic 
Cooperation (Minneapolis, USA), known as Medtronic INFUSE® Bone Graft. 
Ultrapure water from the Milli-Q system (Synthesis, A10) was used. Silk from 
Bombyx Mori was obtained from Silk innovation center, Thailand. Magnetic 
stirrer (Heidolph, Germany) was used for synthesis of particles. ElmaSonic 
220, E60H sonicator was used for sonication and the imaging was conducted 
using Transmitted Light Microscope (TLM, Axiostar Plus, Carl-Zeiss Inc.), 
SEM (Jeol JSM 5600) and Apotome Microscope (Carl-Zeiss Inc.) were used 
for microscopy. Dynamic Light Scattering (DLS) measurements were 
conducted using DLS zeta sizer (Malvern Particle Size analyzer, United 
Kingdom). Centrifuge (Fischer Centrific® Centrifuge, USA) was used for 
washing the nano and yolk shell particles.  Freeze dryer (FreeZone 180, 




BMP-2 was used for enzyme- linked immunosorbent assay (ELISA) 
measurements for determining the loading efficiency and release profile of 
BMP-2. FTIR measurements were conducted FTIR equipment, IR Prestige-21, 
Shimadzu Corp.. 
3.2.2 Preparation and Purification of Silk Fibroin solution (SF) 
Bombyx mori silk fibers (Silk innovation center, Thailand) were degummed in 
0.02M NaHCO3 solution at 90
0
C for 1.5 hours to completely remove sericin. 
Silk fibroin solution was obtained by dissolving sericin-free silk ﬁbers in to a 
ternary solvent system of CaCl2/CH3CH2OH/H2O (1:2:8 in molar ratio) 
followed by dialysis [157]  against de-ionized (DI) water for 4 days at room 
temperature with 12–14 kDa cutoff semi-permeable dialysis tubing. The 
deionized water was changed after 1 hour, 2 hours, 4 hours, 8 hours, 12 hours 
and subsequently after every 24 hours. The concentration of the silk solution 
prepared was measured by taking 1ml of the silk fibroin solution, henceforth 
referred to as SF solution, and drying it at 60
0
C till a film was formed. The 
film was weighed and the concentration of the SF solution was determined. DI 
water was added to make the SF concentration to 6% (w/v, = 60mg/mL) and 
was stored at 4
0
C for further use.  
3.2.3 Synthesis of BMP-2 loaded Silk Fibroin Nanoparticles 
Silk Fibroin nanoparticles were synthesized using a controlled self-assembly 
method using ethanol as a nucleating agent and low temperature treatment.  
40 μL of ethanol (100%) was added to 100 μL of SF solution in an Eppendorf 
tube and vortexed for 20s. Further, 900 μL of 2% PVA mixture was added to 
the ethanol-SF mixture, followed by vortexing for 20s. The experiment was 




concentration used. Each of the SF-ethanol-PVA solutions was incubated in a 
refrigerator at freezing temperature (-20
0
C) for 24 hours. After 24 hours, the 
frozen samples were thawed in a water bath at room temperature and then 
centrifuged at 10,000 rpm for 10 minutes to extract the SF particles. The 
particles were further purified by washing 3 times with deionized water 
(10,000 rpm, 10 minutes). Eventually, dry particles of SF were obtained by 
lyophilization. 1 mg of the collected particles was weighed and incubated with 




pg/mL) in Phosphate Buffered Saline 
(PBS) at 4
0
C and 200 rpm for 12 hours. After 12 hours, the particles were 
separated from the suspension by centrifuging at 10000 rpm for 10 minutes 
followed by washing with deionized water 3 times. 
3.2.4 Synthesis of SF Yolk Shell Particles (YSPs) 
SF yolk-shell particles, or YSPs, were prepared using a modified water in oil 
microencapsulation technique. The SF nanoparticles prepared earlier, were 
dispersed in predetermined ratios in SF solutions of varying concentrations to 
form the aqueous phase. Typically, 2 mg of SF nanoparticles, loaded with 
BMP-2, were dispersed in 2 mL of 1% (w/v) SF solution which constituted the 
aqueous phase. The oil phase comprised of a 1:10 mixture of tween and corn 
oil (food grade). The aqueous phase was added drop by drop to the oil phase 
(spinning at 500 rpm on a magnetic stirrer) and the apparatus was covered 
with a layer of parafilm and allowed to spin overnight. The YSPs were 
harvested by spinning down the suspension for 15 minutes at 10,000 rpm at 
room temperature and discarding the oil through decantation. The pellet was 




The water and oil displayed a clear phase separation and the YSPs were 
collected in the aqueous sub layer. 
 
3.2.5 Characterization of Silk Fibroin Nanoparticles and Yolk Shell 
Particles 
3.2.5.1 Imaging 
After lyophilization, the SF nanoparticles were dispersed in water, sonicated 
for 20 seconds at 40% amplitude and then placed on an adhesive copper tape 
on a metal stud. The samples were sputter coated with platinum using an ion-
sputtering device (Jeol Fine-Coat JFC 1100E, Jeol LTD, Tokyo, Japan) to 
make them conductive and then examined under a scanning electron 
microscope, SEM (Jeol JSM-5400 LV, Jeol LTD, Tokyo, Japan) to observe 
the size, polydispersity and morphology . 
For imaging the YSPs, SF nanoparticles were synthesized by using a SF 
solution which was incubated with RITC for 8 hours at 8
0
C, followed by 
dialysis against DI water.  The SF YSPs once formed, were further incubated 
with 2% (w/v) FITC-Dextran solution before imaging and washed to remove 
the excess FITC-Dextran. The particles were observed using Apotome 
microscope using fluorescence section viewing. SEM was conducted as 
described for the SF nanoparticles. Imaging software Image J 
TM 
was used to 
examine the particles and determine the thickness of the shell and the 




3.2.5.2 Dynamic Light Scattering (DLS) Measurements 
Dynamic light scattering or DLS was used for measuring size, surface charge 
(zeta potential) and plotting size distributions of SF nanoparticles and YSPs. 
All samples prepared were sonicated (40% amplitude) for 20s and then 
analyzed via dynamic light scattering measurements (Malvern Instruments, 
Nano ZS). The samples were diluted till the count of 200 kcps and were 
measured 3 times (15 runs per measurement).  
3.2.5.3 FTIR Measurements 
Conformational changes in SF nanoparticles post the self-assembly process 
were determined using Fourier Transform Infrared Spectroscopy (FTIR). 
Samples were prepared by varying the ratio of ethanol to SF in the reaction 
mixture and harvesting the particles as described before. The samples were 
lyophilized and ground with freshly prepared KBr (1:100 w: w) and made into 
a pellet using a mini hand press. The samples were then placed in the FTIR 
machine (IR Prestige 21, Shimadzu) according to the manufacturer’s 
instructions and the Absorbance spectra was plotted and examined for further 
analysis. Absorbance spectra of PVA was also calculated and subtracted from 
the spectra of all the samples to account for any residual PVA left on the silk 
particles. FTIR spectra of Bombyx Mori silk was used as a reference.  
3.2.5.4 Loading Efficiency of BMP-2 in SF nanoparticles 
The loading efficiency of BMP-2 in the SF nanoparticles was determined by 
calculating the unbound BMP-2 in the supernatant after spinning down the 
BMP-2 soaked silk fibroin nanoparticles and washing the nanoparticles to 
remove unbound BMP-2. The supernatants were analyzed using UV-




till the supernatant did not show any protein absorption peak. BMP-2 
concentration was determined by conducting an ELISA using BMP-2 
conjugate (Quantikine ELISA kit).The assay was conducted in a 96 well plate 
provided by the manufacturer.100 μL of Assay Diluent was added to each well 
followed by the addition of 50 μL of standard, control, or sample per well. The 
plate was covered with an adhesive strip and incubated for 2 hours at room 
temperature on a horizontal orbital microplate shaker at 500 rpm. The wells 
were aspirated and washed with the washing buffer 3 times. 200 μL of BMP-2 
Conjugate was added to each well and incubated for 2 hours at room 
temperature on the shaker. The plate was washed 3 times with the wash buffer. 
This was followed by addition of 200 μL of Substrate Solution to each well 
and incubated for 30 minutes at room temperature on the benchtop in dark. 50 
μL of Stop Solution was added to each well to stop the reaction. The plate was 
read in a microplate reader (Fluostar Optima, BMG labtech) by determining 
the optical density of each well at 450 nm wavelength. Readings were also 
taken at 540 nm to account for the optical imperfections in the plate.  The 
loading efficiency of BMP-2 was calculated by using equation 3.1. 
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3.2.5.5 Swelling and Degradation of SF Yolk Shell Particles 
1 mg SF YSPs were weighed and incubated in 1ml of DI water at 37
0
C. The 
particles were separated by spinning down at 10,000 rpm for 10 minutes. The 
excess water on the surface of the particles was removed by gentle air drying 
and lightly dabbing with a filter paper. The mass of the pellet was measured 
and the difference with the initial amount was regarded as the extent of 
swelling. Readings were taken at 30 minutes, 4 hours and days 1, 2, 5, 8, 10, 
15 and 20 post incubation in DI water. 
The YSPs were then kept in an oven at 60
0
C overnight to remove all the 
absorbed water and the mass was measured again. The difference with the 
initial mass was treated as the extent of degradation. 
3.2.5.6 Measuring Encapsulation Efficiency of SF nanoparticles in Yolk 
Shell Particles. 
Since the size of the SF nanoparticles, which formed the cores of the yolk 
shell structure, was known, a filter was chosen such that: 
Size SF nanoparticles < Cutoff < Size YSPs 
The water in oil emulsion containing the SF YSP’s was filtered through the 
cutoff filter to filter out the unencapsulated SF nanoparticles. The filtrate was 
washed with acetone to remove the oil and thereafter an aqueous suspension 
was made by suspending the pellet in deionized water. The filtrate was 
subjected to DLS measurements for determining the presence of distinct peaks 
representing the nanoparticles and the yolk shell particles. The amount of 
unencapsulated nanoparticles was determined by freeze drying the filtrate and 




                             
                                                                       
                                
  
    ……………………………………………………………………………………Eq. 3.2 
3.2.5.7 Measuring the Release of BMP-2 from SF Nanoparticles and Yolk 
Shell Particles 
1mg BMP-2 loaded silk fibroin nanoparticles as well as 1 mg yolk shell 
particles were incubated at 37
0
C, 200 rpm shaking in 1 mL PBS. The BMP-2 
loading here is mentioned in terms of weight of BMP-2/weight of SF 
nanoparticles. At each timepoint, 800 μL of PBS was removed and analyzed 
for BMP-2 content using a sandwich ELISA assay as describe before. The 
readings were taken every couple of hours till 12 hours and thereafter at days 
1, 2, 4, 6, 8, 10, 12, 17, 17, 21 and 30.  At each timepoint, the samples were 
replenished with an 800 μL of fresh PBS to stimulate sink conditions. The 
kinetics of BMP-2 release were examined by fitting the release data to 
logarithmic (first order) algorithm, Higuchi and Korsmeyer–Peppas models, 
which represented independent systems that described release proﬁles for 
particles, namely diffusion controlled system, swelling controlled system and 
erosion controlled system [158]. 
The logarithmic or first order fitting represented a first order release system. 
Higuchi model described drug release as a diffusion process based on the 
Fick’s law, square root time dependent [159]. Korsmeyer–Peppas was a semi-
empirical equation based on power-law expression to describe the drug release 




Equation 3.3 was used to determine the most appropriate model to describe the 
dissolution data, n was the number of dissolution data points, p was the 
number of parameters in the model and R
2
 was the coefﬁcient of determination 
[159] 
         
     
   
   
          ……………………………………….Eq. 3.3 
3.3 Results and Discussion 
 
3.3.1 Silk Fibroin Nanoparticles 
SF nanoparticles were prepared by a self-assembly method as shown in Figure 
3.1. In the native state, the SF molecules exist as a random coil structure 
containing both hydrophobic and hydrophilic segments. Silk fibroin contains 
mainly hydrophobic segments, (73% of the amino acid residues are 
hydrophobic [64, 160]) but some amino acids with polar side groups, such as 
Ser, Tyr, Glu, and Asp are hydrophilic [161]. Also, silk fibroin contains both 
crystalline and amorphous domains. The amorphous regions impart a poor 
orientation to the silk fibers  but the repeated Gly-Ala sequence tends to form 
the well-oriented anti-parallel β-sheet crystalline regions [162, 163]. The 
transformation from random coil to a more crystalline β-sheet structure can be 
completed by external stimuli such as vibration, agitation, freezing and 
addition of organic solvents [164-166]. These stimuli are believe to influence 
the hydrogen-bond formation to control the silk fibroin crystallization [167-
169]. The initial transition to β-sheet takes place by the addition of ethanol, 
leading to the formation of β-sheet microcrystals as reported by Yamada et al 




for the growth of silk fibroin aggregation into nanospheres with continuous 
stirring [171]. Once the aqueous phase is added to the SF-Ethanol mixture, the 
SF self-assembles in aqueous solution to form distinct structures due to the 
hydrophobic effect, which drives the non-polar region of each polymer 
molecule away from water and towards one another [144]. Polymers 
containing hydrophilic and hydrophobic segments tend to self-assemble in 
various forms such as micelles, vesicles and tubules [172, 173] [[174, 175]. 
The spherical subunit hence produced consists of a crystalline well-ordered 
core, and amorphous phase poor-ordered shell [161]. Once, the spherical 
subunits are formed in the aqueous phase, they coalesce to form a 
microglobule. Subsequent shearing force produced during the gradual 
decrease in temperature during the freezing procedure further induces silk 
fibroin conformational transition [161] to a more crystalline structure and 
separation of subunits from the microglobule [176]. The PVA in the aqueous  
phase prevents the subunits from coalescing eventually leading to the 







Figure 3.1: Mechanism of SF nanoparticle formation:  Silk fibroin in its native state contains 
intermittent hydrophobic and hydrophilic domains. Ethanol treatment causes a conformational change 
from a random coil to a more crystalline β sheet structure. Adding the silk fibroin-ethanol mixture to a 
water-PVA mixture leads to a micelle formation due to hydrophobic interactions. These micellear 
subunits come together to form a fibroin globule which upon freezing leads to the formation of 
individual silk fibroin nanoparticles. 
 
SEM imaging revealed that the particles showed a spherical morphology and 
their shape was consistently spherical throughout the areas that were analyzed 
(Figure 3.2). The size of the particles was calculated (by DLS measurements) 
between 280 nm to 1.5 µm. It should be noted that the size reported by DLS 
measurements was slightly greater than that shown by SEM imaging. This is 
due to the fact that DLS measures hydrodynamic diameter and owing to the 




Figure 3.2: SEM images of silk nanoparticles: A) 30k (inset: dilute sample) ,B) 40k, C) 60k and 
D) 100k magnification used to image the particles. The particles show a spherical morphology and 






The size of the SF particles was analyzed by examining the samples prepared 
by varying the silk fibroin to aqueous phase ratio and the concentration of SF 
used. It was observed that at the same SF to Aqueous Phase ratio, the size of 
the SF particles increased by increasing the concentration of SF used (Figure 
3.3A).  It was further noted that for a given SF concentration used, the size of 
the particles decreased with increasing proportion of aqueous phase during 
synthesis. Stolnik et al  [177] have  explained  this  fact  by  the  greater  
probability  that  the desolvated  macro-  molecules  (or  small  aggregates  
formed  from  these  molecules)  coalesce,  in  a  more  concentrated  solution,  




of PVA in the mixture leads to the formation of smaller SF units and does not 
allow the subunits to coalesce.  For each SF concentration used, the smallest 
size for the SF particles was observed at silk fibroin to aqueous phase ratio of 
1:19. For a given silk fibroin to aqueous phase ratio, the smallest particles 
were formed at an SF concentration of 0.9375 mg/mL (Figure 3.3 A). Using 
SF concentrations lower than 0.9375 mg/mL resulted in a very poor yield of 
SF nanoparticles and using an SF concentration beyond 15 mg/mL (1.5%) 
resulted in coagulated masses of SF in the form of a gel which hindered the SF 
particle formation. For this study the size of the particles was desired to be  as 
small as possible to maximize the surface area to volume ratio for subsequent 
adsorption of BMP-2. For further studies, SF nanoparticles made at silk 
fibroin to aqueous phase ratio of 1:19 were used. It was observed at this 
formulation, the particles showed a narrow variation in size and were 










Figure 3.3: Size and distribution of silk fibroin nanoparticles: A) Variation in SF particle size with 
change in SF concentration and SF to aqueous phase ratio. * indicates significant differences among the 
samples made at different SF to aqueous phase ratio and #,^, and ** indicate significant differences 
between the samples made with different SF concentration. (n=3 for all data points). B) Volume 










Table3.1: Analysis of size, zeta potential and polydispersity index of SF nanoparticles. SD= 
Standard Deviation; PDI= Polydispersity index.  
 
Zeta potential is used to describe the electrokinetic properties of a colloidal 
particle under the influence of an applied electric field [178]. The presence of 
surface charge on the nanoparticles can cause them to show a higher absolute 
value of the zeta potential. The Silk Fibroin nanoparticles were found to 
possess zeta potential in the range of −20.34 to −27.75 mV (Table 3.1). 
The results suggest the presence of negative charges on the surface of the 
nanoparticles [179]. It is believed that the electrostatic repulsion of the 
nanoparticles prevents the polymer chains from uncontrolled agglomeration. 
The surface charge and adsorbed molecules also affect the size distributions of 
nanoparticles in the solvent.  
FTIR spectra provided the required information about conﬁrmation of the 
secondary structure of SF during the various stages of inspection. Samples 
SF:Aq 
(1: 
Conc (%) Size 
(nm) 
SD PDI SD Zeta Potential 
(mV) 
SD 
9 1.5 1103 47.8 0.43 0.09 -22.01 1.20 
12.3 1.5 910 13.4 0.40 0.09 -24.02 2.22 
19 1.5 778 42.4 0.25 0.06 -23.02 1.83 
9 0.75 865 17.6 0.24 0.11 -23.45 0.92 
12.3 0.75 554 9.3 0.29 0.02 -20.34 2.85 
19 0.75 496 11.5 0.17 0.01 -26.78 3.26 
9 0.375 672 24.1 0.21 0.06 -24.57 1.60 
12.3 0.375 542 9.29 0.10 0.01 -23.34 4.53 
19 0.375 392 14.2 0.18 0.04 -22.33 2.41 
9 0.1875 503 8.9 0.25 0.02 -21.78 1.38 
12.3 0.1875 382 3.49 0.17 0.01 -21.25 1.15 
19 0.1875 335 3.37 0.22 0.03 -27.75 0.62 
9 0.09375 396 12.1 0.23 0.02 -23.55 2.93 
12.3 0.09375 319 1.05 0.22 0.08 -24.50 2.15 




were prepared using 1% SF and SF to Aqueous ratio of 1:19. FTIR 
spectroscopy indicates the wavelengths of radiation absorbed by the samples 
and as every compound has a characteristic set of absorption bands in its 
infrared spectrum region, any conformational changes in the structure can be 
observed and noted [156]. Protein and polypeptides show their characteristic 
bands in the spectral regions of Amide I and Amide II.  Silk Fibroin in its 
native state (random coil or Silk I) exhibits sharp Amide II peaks at around 
1540cm
-1
 and Amide I peaks at around 1640 cm
-1  whereas silk fibroin in its β 
state shows Amide II peaks closer to 1530cm
-1
 [156]. Conformational 
changes, as revealed by FTIR measurements, show the presence of β structure 
silk II (Beta) for the SF particles with the peaks at 1637 cm
-1
 (amide I) and 
1535 cm
-1
 for all the formulations (Figure 3.4) . It was seen that for the 
particles with the lowest ethanol to SF ratio a small Silk I amide II peak could 
be seen at 1539cm
-1. 
Thus it can be seen that ethanol is essential for including 




Figure 3.4: Absorbance FTIR spectra of SF nanoparticles: Amide I and II peaks highlighted for each 
formulation. A shift in peaks from the untreated SF samples can be seen, revealing the conformational 





BMP-2 was loaded onto the surface of the SF nanoparticles via adsorption. As 
mentioned in the methodology, the SF nanoparticles incubated with the BMP-
2 solution were spun down and the supernatant was collected. The particles 
were washed with deionized water till the supernatant did not show protein 
absorption peak (280 nm) under UV spectrophotometer. A sandwich ELISA 
was conducted on the supernatants and the sum of BMP-2 content in the 
supernatants (after washing) was treated as the unbound BMP-2. The ELISA 
measurements of BMP-2 loading efficiency show the variation in loading 
efficiency of BMP-2 with a change in the amount of BMP-2 added per unit SF 
nanoparticles (Figure 3.5). It is interesting to observe that increasing the 
amount of BMP-2 added from 0.25 x 10
6
 pg/mg nanoparticles to 1 x 10
6
 
pg/mg nanoparticles causes a significant change (p<0.1, ANOVA) in loading 
efficiency from 56% to 76%. The loading efficiency peaks at 88-90% with 
concentrations of 2 x10
6
 pg/mg nanoparticles and above.  These results show 
that the particles tend to saturate when an excess BMP-2 is added and this 
impeded further adsorption of BMP-2.  Better loading efficiencies of BMP-2 
in silk fibroin particles at lower initial loading have been reported elsewhere 
[180, 181] and an argument might arise as to why BMP-2 , instead of being 
surface adsorbed, was not encapsulated within the SF nanoparticles. The 
reason here is twofold. Firstly, the encapsulation procedure requires the BMP-
2 to be added in solution to the SF solution and ethanol. The idea here is to 
protect the BMP-2 from any organic solvent; hence a passive surface 
adsorption approach was employed. Secondly, since these BMP-2 loaded SF 




BMP-2 is on the surface and not encapsulated within the SF nanoparticles 
becomes redundant as the yolk-shell particles are theorized as point/depot 
delivery systems.  
 
Figure 3.5: Loading of BMP-2 on SF nanoparticles: Plot of percentage BMP-2 adsorbed versus BMP-
2 added per unit SF nanoparticles. SF nanoparticles used were made with 1% SF and SF: Aq =1:19 
(n=3). 
 
3.3.2 Yolk Shell Particles 
Yolk shell particles are called so because of their unique core-void-shell 
configuration. It was observed that an aqueous solution of  SF with 
concentrations between 1–6 mg/mL, when emulsified  in a mixture of corn oil 
and tween (10:1 v/v), resulted in formation of silk microcapsules as explained 
by Hermanson et al [144].  
Here, it was seen that silk fibroin protein from Bombyx mori could be 
assembled at an oil/ water interface to form a microcapsule with encapsulated 
silk fibroin nanoparticles prepared earlier as explained by Figure 3.6. SF has 




oil and water. After adsorption, the silk fibroin protein assembles and forms a 
thin film at the surface of the water droplets, encapsulating its contents. This 
was the principle used in making the yolk shell configuration. The BMP-2 
loaded SF nanoparticles prepared earlier were dispersed in an aqueous SF 
solution (of varying concentrations) and added drop by drop to a rapidly 
spinning oil-tween mixture. Previous studies of  proteins at interfaces have 
shown that proteins will often adsorb and denature at an interface to form a 
film or layer [182, 183]. These studies have shown that the rate of film 
formation for most proteins is slow, since several processes have to take place 
in a defined order: i) protein adsorption, ii) protein unfolding, and iii) protein 
refolding and assembly [183]. Since SF is intrinsically unfolded, no protein 
unfolding has to take place at the interface of the oil and water and hence rapid 
diffusion of the protein takes place and leads to the formation of a SF film on 
the interface. Water from inside the drop diffuses out and this leads to the 
formation of SF YSPs with silk fibroin nanoparticles trapped inside [184] .  
 
 
Figure 3.6: Mechanism of Yolk-shell particle formation: Silk fibroin protein adsorbs at the aqueous 
phase-oil interface and forms a shell trapping the BMP-2 laden SF nanoparticle cores. 
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The water (SF aqueous phase with SF core nanoparticles) in oil emulsion was 
stirred for 2 hours at room temperature at 500 rpm. Once the SF YSPs had 
been formed, the contents of the suspension were centrifuged at 10,000 rpm 
for 15 minutes and the supernatant was removed. This was followed by adding 
deionized water to pellet and centrifuged again. This resulted in a phase 
separation wherein the YSPs were present in the aqueous phase and the 
remaining oil separated as a layer on top, which was subsequently carefully 
removed. The YSPs were washed several times to remove the oil. Traditional 
methods to remove such an oil phase completely would involve solubilizing 
the oil with an organic solvent like acetone or ethanol. This step was avoided 
here to avoid exposing the BMP to an organic solvent. The phase separation 
method to harvest the YSPs even though gave a lesser yield than solubilizing 
with an organic solvent, ensured a bio-friendly environment for the BMP. 
The experiment was repeated by varying the concentration of SF in the 
aqueous phase, the ratio of aqueous phase to oil phase and the loading 
percentage of SF nanoparticles. For imaging purposes, SF nanoparticles made 
with RITC-SF were used. The YSPs, once formed, were soaked briefly with 
FITC-Dextran and then viewed under an Apotome fluorescence microscope 
for sectioning. The fluorescence apotome images reveal a capsule structure 
with red silk fibroin nanoparticles inside (Figure 3.7A). The SEM images 
revealed the spherical morphology of the silk fibroin YSPs (Figure 3.7B).  To 
visualize the yolk- shell structure, a slow spinning speed (100 rpm) was used 
during synthesis and high speed (15,000 RPM for 30 minutes) during 
separation. This resulted in rupturing of some of the particle shells and gave a 




particles were analyzed using ImageJ™ and the thickness of the shell was 
determined. It was found that for a given aqueous phase to oil ratio, increasing 
the concentration of SF in the aqueous phase showed a gradual increase in size 
from about 400 nm (at 0.5% SF in aqueous phase) to 1400 nm (at 3% SF 
concentration) (Figure 3.8) . For a given SF concentration used in the aqueous 
phase, the size of the YSPs increased by increasing the aqueous phase to oil 
ratio from 1:10 to 1:2.5. 
Upon increasing the concentration of SF in the water in oil emulsion, either by 
increasing the concentration of SF used or by increasing the aqueous phase to 
oil ratio or both, bigger droplets of the aqueous phase are formed, resulting in 
formation of bigger particles. The tween in the oil phase does not allow the 
YSPs to coalesce. It was found that by increasing the SF concentration to more 
than 3% and/or increasing the aqueous phase to oil ratio to more than 1:2.5, 
larger aggregates were formed with a very high polydispersity. No significant 
differences among groups were observed at SF concentration of 0.5%. 
 
Figure 3.7: Silk Fibroin yolk-shell particles: A) Fluorescence image of the yolk-shell particles. Inset: 
higher magnification image of these particles shows the red ‘core’ and green ‘shell’. B) SEM image of 
the yolk-shell particles. Inset: a single particle showing the shell structure. The average shell thickness 







Figure 3.8: Effect of SF concentration on size of YSPs: Variation in size of YSPs with changing SF 
concentration in the aqueous phase and by varying the SF: Oil ratio can be seen. The size of the YSPs 
increases with an increase in SF concentration in the aqueous phase and decrease in the ratio of SF: Oil. 
* represents significant differences at the same SF concentration and # indicates significant differences 
among groups formed at the same SF: Oil ratio but different SF concentration. (n=3) 
 
The measurement for the loading efficiency of the SF nanoparticles into the 
yolk shell particles was conducted by measuring the mass of the 
unencapsulated nanoparticles. Loading here is mentioned in percentage weight 
of SF particles/volume of SF solution in aqueous phase. The measurements 
were conducted using an array of loading % and concentrations of aqueous 
phase and SF core nanoparticles with a size of 154 + 5.8 nm were used. The 
change in loading efficiency with a change in silk fibroin concentration used 
in the aqueous phase was not statistically significant. It can be seen that the 
encapsulation process of the SF nanoparticles in the YSPs is independent of 
the concentration of SF used in the aqueous phase for making the SF YSPs 
(Figure 3.9). The encapsulation efficiency also does not vary significantly with 
the change in loading percentage of SF core nanoparticles, provided the 




loading efficiency increased with increasing loading for SF YSPs synthesized 
with 0.5% SF in the aqueous phase. However this trend was not statistically 
significant for other formulations. Using higher loading percentage (0.2% SF 
nanoparticles) and beyond hindered the formation of the YSPs and high 
polydispersity and coagulated masses of YSPs were obtained. The same was 
observed for SF nanoparticles with size greater than 300 nm. Hence the 
optimal loading percentage of SF nanoparticles in the YSPS is between 0.25% 
- 1% w/v of SF nanoparticles with size less than 300nm.  
 
 
Figure 3.9: Loading of SF nanoparticles in SF YSPs: Encapsulation efficiency of silk fibroin 
nanoparticles in yolk-shell particles at different concentrations of silk fibroin in the aqueous phase. 
Loading here is mentioned in terms of weight of silk fibroin nanoparticles added per unit volume of 
aqueous phase (1 % loading = 10 mg nanoparticles/mL aqueous phase). (n=3 for all data points). 
 
 
When studying the swelling and degradation of the YSPS, it was observed that 




water. The swelling measurements demonstrated that the SF YSPs had a 
tendency to swell up to 2x their original mass within the first 30 minutes of 
incubation. The swelling peaks at 500% at day 5 and then plateaus (Figure 
3.10A). This demonstrated the yolk shell particles’ ability to uptake water and 
water soluble molecules. Upon drying the particles and removing the absorbed 
water, it was seen that the weight loss in silk fibroin YSPs was negligible (less 
than 2.5%) over a period of 20 days (Figure 3.10B). The YSPs even though 
tend to swell, are stable in aqueous media and consequently can be used for 




Figure 3.10: Water uptake (swelling) and degradation of SF YSPs in water: A) Change in wet mass 
(swelling) of YSPS with time (B) Change in dry mass  of YSPs with time . (n=3 for all data points). 
 
3.3.3 Release of BMP-2 from SF Nanoparticles and YSPs 
The release study of BMP-2 from the yolk shell particles as well as the silk 
fibroin nanoparticles was conducted in parallel for comparison. Current BMP-
2 dosage ranges from 0.6 – 1.8 x 106 pg BMP-2/mg carrier or around 106 pg 
BMP-2/mL when added in solution [185, 186]. BMP-2 loading similar in 
order of magnitude to those used in literature were used in this study. As 




compare the release profile and kinetics of BMP-2 from the silk fibroin 
nanoparticles as well as the SF YSPs, viz. logarithmic or first order fitting, 
Higuchi Model and Korsmeyer–Peppas model. A coefficient T25, which 
represented the time taken for 25% of the drug to be released, was chosen as 
the representative term for each method used. R
2 
or adjusted coefficient was 
used to evaluate the efficacy of the data fitting algorithm. The closer R
2 
value 
is to 1, the better the data fitting was assumed to be. 
First order or Logarithmic model has been used to describe the release of 
drugs which followed first order kinetics: 
log C = log C0 - Kt / 2.303 ……………………………………………Eq. 3.4 
 where C0 is  the initial concentration of drug, k is the first order rate constant, 
and t is the time. The function has been used to describe the release of many 
water soluble drugs [187-189].  
Higuchi model describes drug release as a diffusion process based on the 
Fick’s law, square root time dependent. It assumes that: 
(i) initial drug concentration in the matrix is much higher than drug 
solubility; 
(ii) drug diffusion takes place only in one dimension;  
(iii) drug particles are much smaller than system thickness;  
(iv) matrix swelling and dissolution are negligible; 
(v) drug diffusivity is constant; and 
(vi) perfect sink conditions are always attained in the release environment 
It assumes the relation 




where KH is Higuchi constant. This relation is valid during all the time, except 
when the total depletion of the drug in the therapeutic system is achieved 
[159].   
Korsmeyer –Peppas model uses a simple relationship which describes drug 
release from a polymeric system equation 
  
  
   
 ………………………………………………………………...Eq. 3.6 
where       is a fraction of drug released at time t, k is the release rate 
constant and n is the release exponent. The n value is used to characterize 
different release profiles [158].  
The release models were used to simulate the in vitro release proﬁles and the 
data is shown in Table 3.2. It was seen that while Logarithmic fitting of the 
data provided a close estimate of the actual values observed for release of 
BMP-2 from the SF nanoparticles, it appeared that the Korsmeyer–Peppas 
model was the best ﬁtting model for the release from the yolk-shell particles. 
The values of n for spheres were <0.43 or 0.43 for Fickian release and 0.85 for 
case II or zero-order release in this model. For systems exhibiting case II 
transport, the dominant mechanism for drug transport was due to polymer 
matrix relaxation. The value of n>0.43 but <0.85 was considered as 
anomalous transport (non Fickian) and referred to the coupling of Fickian 
diffusion and polymer matrix relaxation. The value of n>0.85 was considered 
as super case II transport [158]. 
It can be noted that increasing the loading of BMP-2 (weight of BMP 2 added 
/weight of yolk-shell particles), the T25 increased significantly for both the 
yolk-shell particles, as well as SF core particles and the release kinetic 




lower concentration of BMP-2 is added to the core SF particles, less protein 
(BMP-2) comes in contact with the silk fibroin. Once the loading of BMP-2 
was increased, beside interactions between BMP-2 and silk ﬁbroin, self-
aggregation of BMP-2 would diminish the contribution of swelling effect of 
silk ﬁbroin matrix on its release.  As shown by the degradation results, the SF 
YSPs were stable and did not show any degradation when tested for 30 days; 
hence release due to polymer matrix degradation did not have a significant 
impact on the overall release profile. 
Further, the yolk shell configuration provided a significant increase in the 
sustainability of the release of BMP-2 from the Silk Fibroin nanoparticles. The 
configuration shielded the BMP-2 from being diffused rapidly and hence for a 
given loading, slower release was achieved.  
 
Figure 3.11: Release profile of BMP-2: A) Release of BMP-2 from silk-fibroin core particles with 
time. B) Release of BMP-2 from silk-fibroin yolk-shell particles with time (n=3 for all data points). 
Loading here is mentioned in terms of weight of BMP-2 added per unit weight of silk fibroin 











   












 R2 T25 
(days) 
 R2 adj. T25 
(days) 
 R2 adj. T25 
(days) 
SF 0.06 0.09  0.97 0.11  0.92 0.05  0.57 0.35 
Nano 0.12 0.32  0.96 0.34  0.93 0.36  0.89 0.73 
Particles 0.24 0.50  0.95 0.53  0.97 0.91  0.97 1.24 
            
SF 0.06 0.44  0.90 0.57  0.92 0.47  0.72 2.34 
Yolk-
shell 
0.12 2.48  0.93 1.74  0.98 2.26  0.62 5.62 
Particles 0.24 17.00  0.95 13.3  0.96 13.8  0.81 14.4 
 
Table 3.2: A mathematical analysis of the release profiles of BMP-2 from the silk fibroin 
nanoparticles and yolk shell structure. The release of BMP-2 from the SF nanoparticles complies with 
First order logarithmic fitting while the Peppas model best describes the release from the SF YSPs. Also, 
higher T25 values can be seen for SF YSPs for the same initial loading of BMP-2.  
3.4 Conclusion 
This chapter demonstrated the synthesis of novel Yolk Shell particles made of 
silk fibroin with BMP-2 loaded silk fibroin cores. Silk fibroin nanoparticles 
were prepared by a self-assembly method where ethanol and low temperature 
treatment was used to induce conformational change in SF from random coil 
to β sheet which was confirmed by FTIR measurements. Once optimized for 
size and loading of BMP-2, these particles were encapsulated within a SF shell 
to form yolk-shell particles which possess a unique core-void-shell 
configuration and provide a sustained release of BMP-2. A bio-friendly 
method was used for the assembly of the yolk-shell configuration bypassing 
the use of organic solvents. Maintaining sustained release of BMP-2 and 
maintaining its functionality during and after incorporation into delivery 




bone regenerative applications. Since it is shown that altering the synthesis 
parameters can tune the size and release profile of BMP-2 from these particles, 


























































Development of a Silk Yolk 
Shell Particle-Hydroxyapatite-










While autologous bone graft is still considered as the gold standard for bone 
substitutes during orthopedic surgeries, there are several disadvantages 
associated with it viz. donor site morbidity and a limited supply [3]. Also 
traditional hemostatic agents used during bone graft surgeries, such as bone 
wax, have been found to impede bone growth. Hence, the development of 
viable and functional alternatives to the autologous bone graft, which can also 
provide hemostasis, is needed for bone reconstructive surgery. This chapter 
discusses the development of a moldable putty using SF YSPs developed 
earlier (chapter 3), hydroxyapatite and thrombin. 
Calcium phosphate and sulfates find repeated use in orthopedic applications 
owing to their innate similarity to the natural composition of the bone.  
Cements based on Calcium phosphate and sulfates are a group of materials 
which include a mixture of powders “which, upon mixing with water or an 
aqueous solution to a paste, reacts around room or body temperature by the 
formation of a precipitate containing crystals of one or more calcium 
phosphates and sets by the entanglement of the crystals of that 
precipitate’’[85]. Another member of the calcium phosphate family which 
finds repeated use in bone reconstructive surgery is Hydroxyapatite or HA 
(Ca10(PO4)6(OH)2). It is the naturally occurring mineral component of the 
bone and is osteoconductive and biocompatible [72, 190]. It has the 




osteogenic cell populations. In vivo implantations of  HA have shown 
osteoconduction , a lack of local and systemic toxicity, no inflammation, 
and no foreign body response [84] and direct apposition of new bone to 
hydroxyapatite has been shown without an intervening fibrous layer [84].  
This chapter describes the development of a moldable putty containing 
hydroxyapatite, YSPs and Thrombin.  As established in chapter 3, yolk shell 
particles which provide a sustained release of BMP-2, have successfully been 
developed. However, applying these particles in the form of a suspension at 
the site of the surgery would prove to be futile as they will get washed away 
by the blood flow. Hence maintaining the local position of these particles for         
duration sufficient to initiate and affect the bone healing process is necessary. 
The idea here is to mix the YSPs with hydroxyapatite and use a binding 
medium supplemented with thrombin to form a moldable material (Figure 4.1) 
which can effect a sustained release of BMP-2, provide structural support, 








Figure 4.1: Schematic representation of the YSP-HA-Thrombin putty: The thrombin would be 
present in a matrix of HA and BMP-2 Loaded YSPs. 
 
It is hypothesized that the YSPs when mixed with HA, and the mixture in turn 
treated with an appropriate binding medium supplemented with a pro-
hemostatic agent such as thrombin, will result in a moldable material which 
can provide an adequate release profile of BMP-2 to cause osteogenic 
differentiation of cells and also cause hemostasis upon contact with blood. The 








4.2 Materials and Methods 
4.2.1 Reagents, Materials and Equipment 
Hydroxyapatite (Mw 502.31, synthetic), Thrombin (2000 NIH unit, 
lyophilized) and other chemicals used in this study were purchased from 
Sigma–Aldrich. BMP-2 was purchased from Medtronic Cooperation 
(Minneapolis, USA), known as Medtronic INFUSE® Bone Graft. SF solution 
was prepared from Bombyx Mori silk from Silk Innovation Center, Thailand. 
Ultrapure water from the Milli-Q system (Synthesis, A10) was used. 
Mechanical testing was conducted using Dynamic and Fatigue system (Instron 
Inc.). SU-8 250 photoresist and SU-8 developers were purchased from 
Microchem (Newton, MA). Sylgard-184 (PDMS) was purchased from Teltec, 
Singapore. Spin coater (Cee, Brewer Science) was used to coat the layer of 
SU-8 on the desired substrate. UV-light exposure was done by using UV-light 
source built in the mask aligner (Karl-SUSS Micro Tec.). The intensity of UV 
light was measured by a power meter (Cole-Palmer). Plasma Etcher (March 
Instruments) was used for plasma treatment of the PDMS devices. Hot plate 
(Sawatec.) was used for baking Su-8 at required temperature. Freeze dryer 
(FreeZone 180, Missouri, USA) was used for lyophilization. Quantikine BMP-
2 ELISA kit for BMP-2 was used for ELISA measurements for determining 
the release profile of BMP-2.  
4.2.2 Making the YSP-HA-Thrombin Putty 
The putty comprised of a powder phase and a liquid phase and was made by 
mixing the two components in a ceramic bowl using a ceramic mortar. Briefly, 
lyophilized silk fibroin yolk shell particles with 0.24% (w/w) BMP-2 loaded 




form the powder phase of the putty. Silk fibroin solution supplemented with 
12.5ul (of 100UN/mL) reconstituted Thrombin solution/mL silk fibroin was 
then added incrementally till slurry like consistency was reached.  The slurry 
was stirred manually till it attained a paste like consistency.  
4.2.3 Characterization of the Putty 
The handling properties (Dough Time and Setting Time) of the putty were 
measured according to ASTM F 451-95 [191] and ISO 5883:1992 (E) [192] 
4.2.3.1 Measuring the Dough Time 
The powder and liquid phases of the putty were mixed by repeated strokes of 
the pestle till the components stopped sticking to a surgically gloved finger. 
The time from when all the components had been added, to the time where it 
did not stick to the gloved finger was defined as the dough time [193].  
4.2.3.2 Measuring the Setting Time 
A 1mL syringe (Becton Dickinson) was cut using a surgical scalpel to make it 
into a cylinder and the edges were smoothed out. The piston of the syringe 
was raised and through the open end the putty was packed in using a metal 
spatula. The syringe was then pressed against a sterile blotting paper and the 
piston was lowered to generate uniformly shaped putty pellets. 
The pellets were allowed to set at 37
0
C in 100% humidity in an incubator and 
were monitored periodically by gently indenting it with a surgical needle. The 
putty was assumed to be set when the needle failed to make a dent on the 
surface. The time from when all the components had been added to the time 
where the surgical needle failed to make an indent on the surface of the putty 




4.2.3.3 Mechanical Testing 
The putty pellets prepared as described before, were placed on a metal holder 
and tested for compression loading under a load of 50N and a compression 
rate of 10mm/min using Dynamic and Fatigue system (Instron Inc.). 
Compressive load and compressive extension were plotted and the value of 
compressive strength was calculated at the point of failure. Dicalcium 
phosphate (DCP) samples were also tested for comparison. 
4.2.3.4 Degradation of the Putty 
The degradation of the putty was studied in various incubation media. The 
putty samples were cast using the syringe method and weighed after the 
setting time. The pellets made were then placed in DI water, Dulbecco's 
Modified Eagle's medium (DMEM), and PBS. The media covering the pellet 
was removed periodically and replenished. The removed media was frozen at -
80
0
C and then lyophilized and weighed to determine the disintegration of the 
putty by measuring the % weight loss. At the end of the study, the largest 
remaining mass of the putty was dried and weighed again. 
The largest mass of intact putty samples obtained after the degradation study 
(30 days) were dried at room temperature and subjected to compression testing 
in a manner described earlier.  
4.2.3.5 Release of BMP-2 from the Putty 
The YSP-HA-Thrombin putty pellets with varying levels of BMP-2 loading 
were prepared as described earlier and were placed in 6 mL PBS in a standard 
6 well cell culture plate and incubated at 37
0
C in an incubator. To measure the 




replenished to maintain sink conditions. The supernatant was analyzed using a 
sandwich ELISA assay for the amount of BMP present. The data was analyzed 
by reading the optical density values at 450 nm and 540 nm and a plot of 
cumulative BMP-2 release was plotted against time. The readings were taken 
every couple of hours for the first 12 hours and thereafter at days 1, 2, 4, 6, 8, 
10, 12, 17, 17, 21 and 30.   
4.2.6 Testing the Putty for Hemostatic Ability 
The components of the YSP-HA-Thrombin putty were mixed in a ceramic 
mortar and after the dough time, the material was packed in a custom PDMS 
device. Blood was flown through the device after setting time and was 
analyzed by recording through a high speed camera. The device was fabricated 
as follows: 
4.2.6.1 Channel and Chamber Design 
 The design of channel and chamber was drawn by using Auto-CAD software. 
This design was printed as a plastic photomask for fabrication of master-molds 
by photolithography.  
4.2.6.2 Master Mold Fabrication by Photolithography 
The master-molds were fabricated by spin-coating a layer of SU-8 on a silicon 
wafer at 2000 rpm for 40 seconds. It was soft-baked for 1 minute at 65
0
 C and 
5 minutes at 95
0
C. It was cooled and was exposed through the designed photo-
mask for 100 seconds at a power of 7mW/cm
2
. The Post Exposure Bake (PEB) 
was performed by baking it for 1minute at 65
0
C and temperature was ramped 
to 95
0
C and then for 15 minutes at 95
0
C. It was cooled and developed for 10 




4.2.6.3 PDMS Replica Molding 
 The Silicon-wafer containing SU-8 master mold was vapor-silanized by 
TRICHLORO(1H,1H,2H,2H-PERFLUOROOCTYL)-Silane in a vacuum 
chamber for 15 minutes for easy release of PDMS replica. PDMS polymer 
base and cross-linking agent were mixed in ratio of 10:1 and stirred for 
uniform mixing. It was degassed in a vacuum desiccator. It was poured on SU-
8 mold and baked for one hour at 70
0
C before peeling it out to obtain replica 
of structures in PDMS. 
Two separate devices were fabricated containing a chamber to contain the 
putty and the other deice had a microchannel to facilitate blood flow. The HA-
YSP putty was packed in the PDMS chamber using tweezers and a metal 
spatula. The PDMS devices were treated with Plasma and placed on top of 
each other, and left at 37
0
Covernight to bind with each other.  
4.2.6.4 Analysis of Blood Flow through the Device 
Blood was collected from healthy individuals with their consent and was 
treated with heparin before storage. All samples were used within one hour of 
collection. The blood was diluted to 1/5
th
 its original concentration in PBS and 
flown across the channel at a flow rate of 0.5ul/min. The flow was observed 
under a microscope and recorded using a high speed camera (Phantom, Vision 
Research). Recordings were made 1 minute, 3 minutes and  5 minutes after the 
flow had started over the material. As a control, blood was flown through an 
empty PDMS chamber. Material with no thrombin and material with heparin 
in the binding agent were also tested for comparison purposes. The motion of 
blood flow through the microchannel device and over the putty was recorded 




blood came into contact with the chamber containing the putty. Still images 
were captured from the video and analyzed using Image J
TM
.  
4.3 Results and Discussion 
4.3.1 Making the Putty 
The putty was made by mixing the powder and liquid components with a 
binding medium (Figure 4.2A). The handling properties of the putty were 
described as an initial mixing phase, where the powder and the liquid phases 
were homogenized thoroughly. This was a short phase and lasted for <1 
minute for all formulations. This was followed by a working phase where the 
components were mixed till the mixture attained a non-sticky or dough state. 
The setting phase consisted of the time taken by the dough to harden [194]. 
Initially, a clean glass slab was taken and hydroxyapatite powder and 
lyophilized YSPs were placed in regions containing 10 mg sample of each 
(Figure 4.2B). 400 µL of DI water was placed on the glass slab. Slowly, HA 
and YSP (1:1) were added to the liquid component and mixed using a metal 
spatula. 100 mg of powder component (50 mg HA+50 mg YSP) were added to 
400 µL DI water. 
It was observed that during the working phase of the putty, the resultant 
mixture looked like a colloidal suspension. Powder phase was added 
incrementally till the mixture showed slurry like consistency. This was 
observed at a solid to liquid ratio of 3:1 and this was the powder to liquid ratio 
used in all subsequent formulations. The slurry achieved a paste like 




till the paste stopped sticking to a surgically gloved finger (Figure 4.2C). This 
was defined as the “dough time” of the putty. 
The putty was then packed in the syringe mold as described earlier and 
pressed against a blotting paper. The piston was pushed and a uniform putty 
pellet was obtained (Figure 4.3A, B (i)). The pellet was allowed to set at 37
0
C 
at 100% humidity and was periodically indented with a surgical needle. The 
time since the complete mixing of the components till the time the needle 
failed to make an indent at the surface was defined as the “setting time” of the 
putty.  
The pellet was henceforth immersed in DI water and observed for 24 hours for 
any disintegration. It was found that the pellet disintegrated completely after 
24 hours of incubation (Figure 4.3B (ii)). Silk fibroin solution was explored as 
viable liquid phase (binding medium) and it was observed that putty made 
with silk fibroin as the binding agent retained its shape after 24 hours 
incubation in DI water (Figure 4.3B (iii)). So, the final composition of the 
putty was fixed as follows: 
Powder Phase = HA+YSPs 
Liquid phase = SF solution  







Figure 4.2: Making the YSP-HA-Thrombin putty: A) schematic showing the description of the 

























Figure 4.3: Molding the YSP-HA-Thrombin putty. A) The schematic of the process.  B) (i) The pellet 
obtained . (ii) Putty formed using water as a binding agent after 24 hours incubation in water. (iii) Putty 


















4.3.2 Characterization of the Putty 
Several formulations of the putty were prepared by varying the ratio of 
Hydroxyapatite to yolk-shell particles and the concentration of SF in the 
binding medium; and were tested for their handling properties. Putty made by 
using dicalcium phosphate (DCP) as the powder phase and SF as a liquid 
phase was studied for comparison purpose. It was observed that the dough 
time was in the range of 1.5 to 2.5 minutes for all the test groups (Figure 4.4). 
A decrease in dough time was observed for all groups upon increasing the 
concentration of SF in the liquid phase. For SF concentration of lesser than  
3% (w/v)  in the liquid phase of the putty, for each concentration of SF in the 
liquid phase, the dough time  across groups decreased with increasing YSP 
content in the powder phase. The difference was not statistically significant at 
higher concentrations. At lower SF concentration in the liquid phase, 
increasing the YSP content increases the intra molecular cohesion and hence a 
decrease in dough time is observed with increasing YSP content. However, 
beyond  2% (w/v)  SF in liquid phase, similar dough times are observed for 
groups with different powder phase compositions as it is believed that  
increasing the concentration of SF in the liquid phase supersedes  the intra-
molecular interaction effect between the powder phase and becomes the 





Figure 4.4: Variation in Dough time of the putty: Increase in SF concentration in the liquid phase 
shortens the dough time (n=3 for all data points). 
 
The variation in setting time was also monitored with changing composition of 
the powder and liquid phases of the putty. No significant change in setting 
with variation in SF concentration in the liquid phase was observed (Figure 
4.5). Variation in setting time at a given liquid phase but varying powder 
phase was also not statistically significant. A slight decrease in setting time 
was observed upon changing the concentration of SF to 2% in the liquid phase 
but changing the concentration to 3% failed to have an effect on the setting 
time in all test groups. The main mechanism causing the setting of the putty is 
proposed as the physical crosslinking between the hydroxyapatite and silk 
fibroin particles in the presence of a viscous binding media mediated by the 
evaporation of excess water in the binding agent as reported in the case of 
nano hydroxyapatite and chitosan [195]. The dominating factor here is the rate 




all the experiments were conducted in the same environmental conditions, the 
rate of evaporation was the same across all test groups. Hence, similar setting 
times were observed at different powder and liquid phase compositions. 
 
Figure 4.5: Variation in setting of the putty. Change in SF concentration in the liquid phase and 
change in the composition of the powder phase did not have a significant impact on the setting time of 
the putty. 
 
Mechanical testing of the putty was conducted using a standard compression 
test (Figure 4.6A). Samples were prepared at a fixed powder to liquid ratio but 
the ratio of hydroxyapatite to yolk-shell particles in the powder phase was 
varied. Tests were conducted after the setting time. It was observed that a 
significantly high compressive strength of 5 MPa, as compared to that of pure 
hydroxyapatite, DCP cement and hydroxyapatite to yolk-shell particles < 10:1, 
was observed for the putty made with pure HA:YSP 0:1  in the powder phase 
(Figure 4.6B). Putty made by mixing hydroxyapatite to yolk-shell particles in 
the ratio 1:1 also showed higher compressive strength than others those with 
lower yolk-shell particle components. Increasing the hydroxyapatite content 
did not cause a significant change in the compressive strength. A study by 




strength versus water: cement ratio in cements showed that for a given liquid 
to solid ratio, reducing the aggregate to cement ratio reduced the compressive 
strength of the cement mixture. The result was attributed to the entrapped air 
which remained after compaction [198]. It can be seen that the YSPs in 
themselves show a high compressive strength when made into a putty due to 
physical crosslinking between the silk fibroin molecules in the YSPs and in 
the binding medium. Increasing the HA content of the putty decreases the 
homogeneity of the powder phase and creates air gaps upon compaction which 
cause a decrease in compressive strength with increasing HA content and 






Figure 4.6: Mechanical strength of the putty measured after the setting time: A) Compressive 
testing of the putty samples and the load extension graph used to calculate compressive strength. B) 









4.3.3 Degradation of the Putty 
The stability of the putty was measured by measuring the mass of the 
disintegrated components in the suspension medium. Putty samples were made 
by varying the hydroxyapatite to yolk-shell particle ratio in the powder phase 
of the putty and incubating the pellets in deionized water, phosphate buffered 
saline (PBS) and Dulbecco’s Modified Eagle Medium (DMEM) (Figure 
4.7A). It was seen that putty samples with the hydroxyapatite to yolk-shell 
particle ratio of 25:1, 10:1 and 5:1 showed no significant variation in 
mechanical strength (Figure 4.6) hence the following samples were chosen for 
the degradation study (at solid: liquid ratio of 3:1 and 2% SF as binding 
medium): 
HA: YSP = 1:0 
HA: YSP = 10:1 
HA: YSP = 1:1 
HA: YSP = 0:1 
The mass of disintegrated fragments of the putty was calculated at day 1, 7, 15 
and 30 of the study and at the end of 30 days, the largest mass of intact putty 
remaining was weighed. While no significant disintegration was observed in 
putty made with hydroxyapatite to yolk-shell particle ratio of 0:1 (Figure 
4.6B), the samples with hydroxyapatite to yolk-shell particle ratio of 10:1 
showed complete disintegration during the course of the study (Figure 4.6 C). 
The variation in weight loss of the putty can be seen in Figures 4.8 A-D. It was 




component (hydroxyapatite: yolk-shell particles 0:1) showed a 20% weight 
loss in deionized water over 30 days. The putty was found to be more stable in 
PBS and DMEM but the difference was not significant and could be also due 
to variation in loss during supernatant extraction, and weighing of the largest 
remaining mass. A comparison of the total weight loss across putty samples 
after the duration of the degradation study revealed that increasing the ratio of 
hydroxyapatite in the putty mixture caused a greater loss in mass across all 
solvents with upto 60% weight loss in samples with hydroxyapatite to yolk-
shell particle ratio 10:1 (Figure 4.8 D). 
Mechanical testing of the putty samples after the duration of the degradation 
study showed that after 30 days of incubation in deionized water, PBS, and 
DMEM; the compressive strength increased for each test group (Figure 4.9).  
It can also be seen that even though the initial compressive strength of the two 
test groups differs significantly, the compressive strengths of the two groups 
after incubation in liquid media show no significant difference. Test groups 
with hydroxyapatite to yolk-shell particle 10:1 showed significant 
disintegration after being incubated for 30 days and were not viable for 
mechanical testing. It is interesting to note the reinforcing effect in aqueous 
environment on the crosslinking and stability of the putty made by using an 
increased amount of yolk-shell particles. It should be noted that SF in its 
native state occurs in a random coil structure owing to its highly cohesive 
nature and intramolecular forces of attraction. The increase in mechanical 
strength can be attributed to physical crosslinking and hydrogen bond 
interactions between the yolk-shell particles (alone or in conjunction with 





Figure 4.7: Degradation study of the putty in various media: A) Samples after 24 hours in (i) DMEM 
(ii) PBS and (iii) DI water . B) Putty with HA:YSP=0:1 after 30 days incubation in PBS. C) Putty with 











Figure 4.8: Weight loss in putty with time in different incubation media: Progressively weight loss 
in samples made with HA:YSP A) 0:1. B) 1:1 and C) 10:1. D) Comparison of total weight loss after 30 





Figure 4.9: Comparison of compressive strength before and after incubation in various media: A 
significant increase in compressive strength after incubation in various media can be seen..* and ** 
indicate significant differences between initial and final values of compressive strength for their 
respective groups and *** indicates significant difference between the initial values of the different 










4.3.4 Release of BMP-2 from the Putty 
The release profile of BMP-2 from the putty made with yolk-shell particles 
with 0.24, 0.12 and 0.06% BMP-2 loaded cores was studied in a manner 
similar to that employed while studying the release of BMP-2 from yolk-shell 
particles. The putty was made with 1:1 ratio of hydroxyapatite to YSPs and 
2% SF was used in the liquid phase. It was observed that increasing the BMP-
2 loading in the yolk-shell particles resulted in a more sustained release profile 
for BMP-2 (Figure 4.10) from the putty. It was also seen that the release of 
BMP-2 was slower as compared to yolk-shell particles and silk fibroin 
nanoparticles for similar loading (Table 4.1). For all subsequent studies, the 
putty was made with YSPs containing 0.24% BMP-2 loaded SF nanoparticles. 
Having a slower release profile would mean a better retention of BMP-2 than 
from point delivery systems. A better retention would also mean shielding the 











Table 4.1: Comparison of release profiles of BMP-2 from SF nanoparticles, SF YSPs and YSP-HA 
Putty: A Table comparing the T25 values observed for release under various BMP-2 loading for SF 




Figure 4.10: Cumulative release profile of BMP-2 from the putty: Cumulative release profile of 
BMP-2 from the putty with time. Loading here is mentioned in terms of BMP-2 loading of the yolk shell 
particles which make up the putty. (n=3 for all data points) 
 
 
4.3.5 Testing the Putty for Hemostatic ability  
 
Once the composition of the putty was optimized, 12.5 µL of 100 UN/mL of 
reconstituted Thrombin/mL silk fibroin was added to the liquid phase of the 
putty. The PDMS device which was fabricated was designed as shown in 
Figure 4.11 A and B. The device contained identical inlets and outlets for 
BMP-2 Loading (%) T25(d) SF 
Nanoparticles 
T25(d) SF YSPs T25(d) YSP-HA-putty 
0.06 0.09 0.44 6.68 
0.12 0.32 2.48 27.95 




blood flow and was direction insensitive. The device had a channel width of 




It was observed that as soon as blood came in contact with the putty, there was 
absorption of blood on the surface of the putty due to the porous nature of the 
putty and the capillary action of the surface. Initially blood was flown through 
an empty chamber and to ensure that there was no clotting seen in blood. This 
was important to establish that PDMS does not cause clotting of blood. 
Blood was flown over the putty with no thrombin added in the liquid phase. 
The flow was captured 1 minute, 3 minutes and 5 minutes after the flow had 
started. Similarly, blood was flown over the putty made with thrombin 
(12.5µL/ mL SF of 100UN/mL/). The areas chosen for analysis were the 
channel length before the blood came in contact with the putty and the channel 
length after the blood came in contact with the putty (Figure 4.11 A). Still 
images were captured from the video and analyzed using Image J (Figure 4.12 
A). The videos were captured at a rate of 30 frames per second and the 
average number of cells per frame was calculated for a time period of 1 
Figure 4.11: PDMS device for blood flow over the putty: A) Frontal view of the device showing the 
sandwich PDMS device with the channel overlaying the putty containing hexagonal chamber. Regions 
A and B are the regions chosen for analysis. B): Frontal view of a section of the device indicating the 




second. Comparing to blood flow before the blood came in contact with the 
putty, a reduction of 65.8 (+ 4.2)% was seen in the number of blood cells per 
frame over the period of 5 minutes, after the blood had come in contact with 
the putty not containing any thrombin (Figure 4.12 B). This could be attributed 
to absorption of blood by the material. This reduction in number of blood cells 
was more pronounced in case of the putty containing the thrombin and was 
calculated to be 74.7 (+ 5.9)% (Figure 4.12 C). The additional increase in the 
reduction of blood cells indicated the active clotting process that the blood was 








Figure 4.12: Blood Cell Number analysis before and after contact with the putty: A) A typical still 
from video converted to a binary image for counting. B) Reduction in cell number with time for blood 
flown over the putty not containing thrombin. C) Reduction in cell number with time for blood flown 






The videos revealed that when the putty with thrombin (12.5µL/ mL SF of 
100UN/mL/) was tested, blood began to clot within 1 minute of the start of 
flow (Figure 4.13 A). Clot formation in analogous region for the device 
containing the putty without the thrombin did not show any clotting (Figure 
4.13 B). From still images acquired from the videos, the area covered by the 
clot was calculated and it was seen that the clot acquired 15.9 % of the area of 
the channel 1 minute after flow had started. The size of the clot increased with 
time as the clot acquired 18.1% after 3 minutes and 24.3% of the area after 5 
minutes of flow over the thrombin containing putty (Figure 4.13 C). No 





Adding the thrombin to the liquid phase of the putty puts the YSPs in contact 
with it. As shown in chapter 3, SF particles show excellent surface absorption 
of proteins. Here too, the YSPs in the matrix absorb the thrombin which is 
released into the bloodstream when it comes in contact with the material 
causing the blood to clot. The putty in these experiments was made with YSPs 
400 nm in diameter and commercially obtained HA powder containing 200nm 
HA particles. Had we used bigger HA particles for making the putty, it would 
have created air gaps in the putty upon compaction and hence more blood 
would have been absorbed. However, using smaller YSPs meant that the 
thrombin had a greater surface area (per unit volume) to adsorb onto and 
1 min.  
3 mins.  
5 mins  
Figure 4.13 Formation of 
blood clot upon contact with 
the putty. A) Clot formation 
after 1 minute, 3 minute and 5 
minutes of blood flow over 
the putty containing thrombin 
and putty without thrombin 
B). C) Area occupancy of clot 
with time  in putty containing 
thrombin and putty without 




hence a better adsorption and release of thrombin could be expected. 
Moreover, using larger YSPs would have compromised the structural integrity 
of the putty by creating a size mismatch with HA. 
4.4 Conclusion 
It was seen that the YSPs prepared in chapter 3, can be used in combination 
with HA and a suitable binding medium to form a moldable putty with high 
compressive strength and good handling properties. This putty can release the 
encapsulated growth factors over a sustained period of time and can also serve 
as a matrix for trapping pro hemostatic factors such as thrombin which can 





































Chapter 5: Biocompatibility 
and Bioactivity Testing of SF 







Chapter 5- Biocompatibility and Bioactivity Testing of SF Yolk Shell 
Particles and YSP-HA Putty 
 
5.1 Introduction 
After characterizing the yolk shell particles and the putty, it was important to 
test their behavior in an in vitro environment. In vitro tests are a subclass of 
experimental biology and provide a great platform for faster, more detailed 
and effective methods of testing the efficacy of biomaterials for their intended 
clinical use. They are traditionally conducted using cells and or components of 
an organism that have been isolated from their biological surroundings to give 
a more detailed and convincing analysis that can’t be done otherwise. 
Living organisms have a very complex hierarchical organization of genes, 
protein molecules, RNA molecules, small organic compounds, inorganic ions 
and complexes in a spatially constrained environment by membranes, organs 
and organ systems [199]. This immense complexity of living organisms makes 
it difficult to identify and isolate individual components that might be affected 
under the influence of a change in in environment due to a chemical or a 
physical stimulus. The main advantage of in vitro work is that it provides a 
simple model to study the individual parameters that combine to form a 
biological response. The purpose of this chapter is to study the effect of the 
YSPs and the YSP-HA-Thrombin putty in a simulated biological environment. 
Experiments were conducted to examine the cytotoxicity, influence on 
bioactivity, and the osteogenic potential of the YSPs and the putty. C2C12 




C2C12 cell line is an immortal line of mouse skeletal myoblasts originally 
derived from satellite cells from the thigh muscle of a two month old female 
C3H mouse [200]. These cells differentiate well into myocytes under 
appropriate culture conditions, and to osteoblasts under a differentiation 
media. The cells are adherent in culture and grow as undifferentiated 
myoblasts in growth medium (Supplemented with Fetal Bovine Serum). 
C2C12 cells have also been used for screening the osteogenic activity of 
BMPs [201-204]. The inherent nature of the cells to not express significant 
amounts of endogenous BMPs makes them an effective tool to test the activity 
of BMPs released from the material being tested. 
The YSPs were studied in a 2 dimensional (2D) as well as a 3 dimensional 
(3D) environment to simulate in vivo environment. The 2D model was 
employed as reported commonly by culturing the cells in a flask with surface 
area 75 cm
2
 in a growth medium supplemented with Fetal Bovine Serum and 
the material to be tested. A 3D model was created by co-suspending cells in 
media containing YSPs and then spinning down the suspension (Figure 5.1). 
This created a pellet containing a homogenous mixture of cells and YSPs, not 
only recreating the in-vivo conditions of the putty, but also a 3D model to 
study the effect on not only the cells that attach to the surface, but also on the 





Figure 5.1: Schematic representation of the 3D model used: The co suspension of cells and YSPs 
(left) when centrifuged together at 200g for 10 minutes, forms a pellet with homogenous mix of the cells 
and YSPs. 
 
5.2 Materials and Methods 
5.2.1 Reagents, Material and Equipment 
C2C12 Mouse Myoblasts were purchased from ATCC. Alizarin Red, Alamar 
Blue, 4',6-diamidino-2-phenylindole (DAPI), Fetal Bovine Serum (FBS), 
Dulbecco's modified Eagle's medium (DBM) and other dyes and chemicals 
used for the experiments were purchased from BioRad, La Jolla, CA. BMP-2 
was purchased from Medtronic Cooperation (Minneapolis, USA), known as 
Medtronic INFUSE® Bone Graft. Ultrapure water from the Milli-Q system 
(Synthesis, A10) was used. Primers for Reverse Transcription Polymerase 





5.2.2 Cell Culture 
C2C12 mouse adherent myoblasts were grown in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with heat-inactivated 10% fetal bovine serum 
and 1% antibiotics (Penicillin/Streptomycin (P/S)) at pH 7.5. The cell line was 
maintained in a 5% CO2 atmosphere at 37
0
C. Cells were allowed to attain 60-
70% confluence and then split into flasks using standard Trypsinization (as 
described in the subsequent sections)  followed by re-suspension in the media. 
5.2.3 Testing the YSPs for Cytotoxicity, Cellular Uptake and effect on 
Osteogenic Differentiation of C2C12 cells 
5.2.3.1 Cytotoxicity  
Cells were trypsinized from subconfluent cultures by adding 1 mL of trypsin 
solution to T75 Falcon flasks with confluent cells followed by 5 minutes 
incubation at 37
0
C with regular gentle shaking. 5 mL DMEM (with 10% FBS, 
1% P/S) was added to stop the reaction. The cell suspension was then 
centrifuged at 200g for 5 minutes at 20
0
C. The cell pellet was suspended in 5 
mL of medium with 10% FBS and thoroughly mixed by repeated pipetting. 
Cells were then counted with a Fuchs–Rosenthal hemacytometer and seeded 
into triplicate wells of a 24-well plate at a density of 10,000 cells per well and 
incubated at 37
0
C for 24 hours. The media was removed and supplemented by 
new media containing the YSPs in different concentrations. Lyophilized YSPs 
were sterilized by plasma treatment prior to addition. The media was changed 
and supplemented with fresh media and YSP mixture every 3 days. After the 
designated time points (24 and 72 hours post addition of YSPs), Alamar blue 




for 3 hours. AB added to the culture medium (no cells) was used as a negative 
control group. The absorbance of test and control wells was read at 570 and 
600 nm with a standard spectrophotometer. The number of viable cells 
correlates with the magnitude of dye reduction and was expressed as 
percentage of AB reduction [205-207]. The calculation was done according to 
the manufacturer’s protocol, using equation 5.1: 
                (
                         
                             
)       
…………………………………………………………………………Eq. 5.1 
In the formula, ελ1 and ελ2 are constants representing the molar extinction 
coefficient of AB at 570 and 600 nm, respectively, in the oxidized (εox) and 
reduced (εRed) forms. Aλ1 and Aλ2 represent absorbance of test wells at 540 
and 600 nm, respectively. A’λ1 and A’λ2 represent absorbance of negative 
control wells at 570 and 600 nm, respectively. The values of percentage AB 
reduction were corrected for background values of negative controls 
containing medium without cells.  
To conduct a Live-Dead cell assay, a separate study was conducted. After 12, 
24 and 72 hours post the addition of YSPs, the media was removed from the 
wells and 400 µL of 3 µM Calcein dye and 400 µL of 2.5 µM Propidium 
Iodide (PI) dye was added and the plates were incubated at 37
0
C for 30 
minutes. After the incubation time, the plate was observed under a 




5.2.3.2 Cellular Uptake/Internalization of YSPs 
C2C12 cells were trypsinized from subconfluent cultures by adding 1 mL of 
trypsin solution to T75 Falcon flasks with confluent cells, followed by 5 
minutes incubation at 37
0
C with regular gentle shaking. 5 mL DMEM (with 
10% FBS) was added to stop the reaction. The cell suspension was then 
centrifuged at 200 g for 5 minutes at 20
0
C. The cell pellet was suspended in 5 
mL of medium with 10% FBS and thoroughly mixed by repeated pipetting. 
Cells were then counted with a Fuchs–Rosenthal hemacytometer and seeded 
into triplicate wells of a 24-well plate at a density of 10,000 cells per well and 
incubated at 37
0
C for 24 hours. After 24 hours, the media was removed and 
replenished with media containing 5 µg/mL YSPs. Prior to addition, YSPs 
were soaked in 1 mL of 100 µg/mL of FITC-BSA overnight at 4
0
C and 
washed with DI water 3x (5000 rpm, 10 minutes). The cells were fixed by 
incubating with 10% Formaldehyde for 15 minutes after which the fixative 
was removed and the wells washed with PBS. The cells were stained with 300 
µL of DAPI per well, diluted to 200 nM and incubated for 5 minutes.  
The cell plate was viewed under a confocal microscope with illumination by a 
980 and a 480 nm laser. A z-stack of the images was created for both green 
and blue fluorescence and the images were rendered using the software 
provided by the manufacturer. 
5.2.3.3 BMP-2 Activity: Alkaline Phosphatase Assay 
C2C12 cells were trypsinized from a confluent T75 cell culture flask and 
resuspended in 5 mL of culture media. 10 mg of silk fibroin nanoparticles 




added to the media. The co suspension of the cells and test particles was 
centrifuged at 200 g for 15 minutes and the supernatant was discarded and 
replaced by 5 mL of culture media.  Cell pellet with no yolk-shell particles 
was used to measure the basal ALP activity and cell pellet grown under 
DMEM supplemented with the same amount of BMP-2, added in solution, as 
added to the test groups, was used as a positive control. The calculations were 
done using the loading efficiency data obtained earlier. The nanoparticles and 
YSPs were maintained in media and this media was used to replenish the spent 
media every 3
rd
 day for their respective test group. After 7 days, the media was 
removed and the cells were washed 3x with PBS to remove any debris. The 
cells were then lysed using 200ul of cell lysis buffer per well and incubating 
for 15 minutes at 37
0
C. The lysate was removed and centrifuged at 10,000 rpm 
for 10 minutes and the supernatant was collected. 50 µL of the filtered lysate 
was added to 100 µL of 1mM/mL solution of para-Nitrophenylphosphate 
(PNPP) in buffer and incubated at room temperature for 1 hour till a stable 
yellow color reaction product was seen. The reaction was stopped by adding 
50 µL of 2N NaOH solution. The resultant suspension was analyzed for 
absorbance at 405 nm to get the ALP activity and the total protein 
concentration of the lysate was determined by a standard Bradford assay of the 
lysate. The ALP activity was calculated using a calibration curve of standard 
Alkaline Phosphatase.  
5.2.3.4 Alizarin Staining 
For the alizarin red staining, C2C12 cells were trypsinized and removed from 
cultures as described before and were seeded at a density of 10,000 cells/mL 




10 mM b-glycerophosphate, in the presence of BMP-2 loaded SF 
nanoparticles and YSPs. BMP-2 was also added as a control to the culture 
media making sure the amount of BMP remains constant across each well. 
Media and particles were replaced every 3 days. After 7 days of culture, the 
cells were washed three times with phosphate-buffered saline and fixed in 4% 
(v/v) formaldehyde for 30 minutes. After removal of the fixative, cells were 
washed twice with distilled water and covered with alizarin red 1% solution, 
pH adjusted to 4.2 followed by gentle agitation in an orbital shaker for 10 
minutes. The solution was then removed and the cells were washed three more 
times with distilled water and viewed under a phase contrast microscope. 
5.2.3.5 mRNA Extraction and RT-PCR 
C2C12 cells were trypsinized from a confluent T75 cell culture flask and 
resuspended in 5 mL of culture media. 10 mg of test materials viz. silk fibroin 
nanoparticles with loaded BMP-2, and YSPs were added to the media. The co- 
suspension of the cells and test particles was centrifuged at 200 g for 15 
minutes and the supernatant was discarded and replaced by 5 mL of 
osteogenic differentiation media (DMEM with 10% FBS, 1%P/S, 100 mM 
ascorbic acid and 10mM b-glycerophosphate ). Cell pellet with differentiation 
media containing BMP-2 added in solution was used as a positive control. The 
media in all test groups was replenished every 3
rd
 day. The gene expression of 
C2C12 cells was determined by RNA extraction followed by Polymerase 
Chain Reaction (PCR) for specific genes, after culturing for 7 days. After 7 
days, the culture media was removed and the pellet was lysed by adding 1 mL 
of Trizol reagent. Total RNA was subsequently isolated according to the 




genomic DNA contamination in RNA samples. Purified RNA was stored at -
80
0
C. The total RNA concentration was determined spectrophotometrically at 
260 nm.  
Complementary DNA (cDNA) was synthesized by incubation of 500ng of 
total RNA with Iscript buffer (BioRad), Reverse Transciptase (BioRad) and 
RNAse-free water. DNA was amplified using a BioRad thermocycler by 
incubating the samples at 35
0
C for 5 minutes, 42
0
C for 30 minutes, 85
0
C for 5 
minutes and finally holding at 4
0
C. To perform a semi quantitative analysis of 
samples, a series of PCR cycles were subjected to evaluate the linear 
amplification range for each primer set. The final reaction system was a 25 µL 
PCR mixture, containing 5 µL Primer mixtures (specific to the genes being 
tested), 12.5 µL iQSYBR Green Supermix (BioRad), 4 µL diluted cDNA and 
3.5 µL RNAse free water. PCR program was carried out at 95
0
C for 3 minutes 
, followed with 40– 45 cycles at 950C for 10 s, 580C for 30 s, and 720C for 60 
s, and then extended at 95
0
C for 1 minutes , 55
0
C for 1 minutes and then 55
0
C 
for 10 seconds. Each cDNA sample was amplified with the optimal cycle 
number for each target gene and an 81 cycle camera melt curve was generated. 
The genes analyzed were Runt-related transcription factor 2 (RUNX2), 
Osteocalcin and Collagen 1 for osteogenesis (Table 5.1). The level of 
expression of the target gene was normalized to Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH, Table 5.1). The data was analyzed according to 






5.2.4 Testing the YSP-HA-Thrombin Putty 
5.2.4.1 Cytotoxicity  
Cells were trypsinized from subconfluent cultures by adding 1 mL of trypsin 
solution to T75 Falcon flasks with confluent cells followed by 5 minutes 
incubation at 37
0
C with regular gentle shaking. 5 mL DMEM (with 10% FBS) 
was added to stop the reaction. The cell suspension was then centrifuged at 
200g for 5 minutes at 20
0
C. The cell pellet was suspended in 5 mL of medium 
with 10% FBS and thoroughly mixed by repeated pipetting. Cells were then 
counted with a Fuchs–Rosenthal hemacytometer and seeded into triplicate 
wells of a 96 well plate containing the YSP-HA-Thrombin putty (as developed 
in Chapter 4) and HA putty as a control at a density of 3,000 cells per well and 
incubated at 37
0
C for 24 hours. All putty samples were sterilized by Plasma 
treatment for 20 minutes prior to addition to culture media. After the 
designated time points (24 and 72 hours), Alamar blue reagent was added to 
the cultures and further incubated for 3 hours. Alamar Blue added to the 
culture medium (no cells) was used as a negative control group. The 
absorbance of test and control wells was read at 570 and 600 nm with a 
standard spectrophotometer. The number of viable cells correlates with the 
magnitude of dye reduction and is expressed as percentage of AB reduction 
[205-207]. The calculation according to the manufacturer’s protocol: 
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In the formula, ελ1 and ελ2 are constants representing the molar extinction 
coefficient of AB at 570 and 600 nm, respectively, in the oxidized (εox) and 
reduced (εRed) forms. A λ1 and A λ2 represent absorbance of test wells at 540 
and 600 nm, respectively. A’λ1 and A’λ2 represent absorbance of negative 
control wells at 570 and 600 nm, respectively. The values of percentage AB 
reduction were corrected for background values of negative controls 
containing medium without cells.  
5.2.4.2. Alizarin Staining and Quantification of Calcium Content 
The method to perform the alizarin staining was the same as that described in 
section 5.2.3.4.2. The cells were seeded onto YSP-HA-Thrombin putty and 
HA putty (control) at a density of 3000 cells per well in a 96 well plate and 
incubated for 7 days under differentiation media (DMEM with 10% FBS, 100 




After 7 days of culture, the wells were washed three times with phosphate-
buffered saline and fixed in 4% (v/v) formaldehyde for 30 minutes. After 
removal of the fixative, wells were washed twice with distilled water and 
covered with alizarin red 1% solution, pH adjusted to 4.2 followed for 10 
minutes. The solution was then removed and the wells were washed three 
more times with distilled water and viewed under a phase contrast microscope. 
For quantification of the calcium content, putty samples (HA-YSP-Thrombin 
and HA) were seeded with cells and incubated for 7 days under differentiation 
media. Calcium Colorimetric Assay Kit (Biovision) was used and the 




amount of Calcium (extracellular) was determined in each well using the 
standard calcium calibration curve. 
5.3 Results and Discussion 
5.3.1 Testing the YSPs for Cytotoxicity, Cellular Uptake and effect on 
Osteogenic Differentiation of C2C12 cells 
5.3.1.1 Cytotoxicity of YSPs 
Alamar Blue assay is a non-destructive way of determining the cell number 
and hence can be used to measure the cytotoxicity of materials being tested. 
When added to cell cultures, the oxidized form of the AB enters the cytosol 
and is converted to the reduced form by mitochondrial enzyme activity by 
accepting electrons from NADPH, FADH, and NADH as well as from the 
cytochromes. This redox reaction is accompanied by a shift in color of the 
culture medium from indigo blue to fluorescent pink, which can be easily 
measured by colorimetric or fluorometric reading [209]. 
Measurement of percentage reduction in Alamar Blue in C2C12 cells 
incubated with YSPS shows that the YSPs in general exhibit a similar 
reduction in Alamar Blue as compared to the control cells incubated sans the 
YSPs, (Figure 5.2). However it can be seen that the percentage reduction in 
Alamar Blue decreases with an increase in concentration of the YSPs till the 
particles are added to a concentration of 5 mg/mL of media. Upon increasing 
the concentration of YSPs to 10 mg/mL, an increase in reduction of Alamar 
Blue can be seen.  Increase in concentrations of YSPs would reduce the 




increase their effective concentration influencing the thermodynamic activity 
of cellular components [210]. This phenomena has been referred to as 
molecular crowding  [211] wherein the cells proliferate faster and in a better 
manner when presented with a higher surface area to attach upon.  The 
increase in particle concentration to 10 mg/mL provides a very high surface 
area to the cells in addition to the plate area and hence a higher cell number 
and consequently, better Alamar Blue reduction than control group is observed 
 
Figure 5.2: Alamar blue reduction by cells incubated under SF YSPs:  Reduction in Alamar Blue 
after the incubation with yolk-shell particles (normalized to control).* Indicates significant differences. 
(n=3) 
 
These results indicated that the yolk-shell particles do not have a negative 
impact on the viability of the cells when incubated with them. It was important 
to establish the non-cytotoxic nature of these particles as their potential to be 
used for biological applications depends on how they would influence the 
viability of cells which come in their contact.  
Apart from quantitative measurements, other assays such as Live Dead Cell 
Assays can also be used to monitor cell viability, and consequently the 




simultaneous determination of live and dead cells by measuring intracellular 
esterase activity and plasma membrane integrity. The principle of the assay 
relies on the innate ability of live cells to exhibit intracellular esterase activity 
which can convert the otherwise non fluorescent Calcein to being intensely 
fluorescent [215]. The dye is polyionic in nature and is well retained within 
live cells producing a uniform green fluorescence in live cells (excitation 
emission 495 -515nm). PI on the other hand does not permeate live cells but 
enters cells with damaged membranes and undergoes a 40 fold enhancement 
of fluorescence upon binding to nucleic acids thereby producing a bright red 
fluorescence in dead cells ( 496- 635 nm). The dyes are non-fluorescent before 
interacting with cells. 
For conducting a Live-Dead cell assay a representative sample of 5 mg/mL of 
YSPs was chosen. It was observed at this concentration; the particles covered 
the base of the cell plate completely and hence also mimic the conditions of 
incubation under the putty. It can be seen that very little or no dead cells are 
observed after 3 days of culture (Figure 5.3). 
 
Figure 5.3: Live Dead Assay of cells incubated with SF YSPs:  Live-Dead cell assay after incubation 
with 5mg/mL concentration of YSPs after A) 12 hrs. B) 24 hours and C) 72 hours. Green fluorescence 





5.3.1.2 Cellular Uptake of YSPs 
To see how the YSPs interact with cells upon contact, the location of the YSPs 
was determined via confocal microscopy. The YSPs were fluorescently tagged 
with FITC-BSA and the cells were stained with DAPI. DAPI is a nuclear due 
and passes through the cell membrane to bind with the A-T rich sequences in 
DNA [216]. When the images taken with their respective excitations were 
layered and stacked, it was seen that even after 24 hours of incubation, the 
particles were present around the periphery of the cells and were not found 
near the nuclear region (Figure 5.4). This is also corroborated by the almost 
negligent cytotoxicity of the particles as shown earlier. This would be essential 
in maintaining the prolonged release of BMP-2 in vivo and maintaining the 
structural integrity of the putty system.  
 
 
Figure 5.4: Internalization and Cellular Uptake of Sf YSPs: 2D representation of the internalization 
of particles after A) 4 hours and  C) 24 hours of incubation. B) and D) are 3D representation of A) and 






5.3.1.3 Effect on Bone Regeneration 
 
5.3.1.3.1 BMP-2 Activity: Alkaline Phosphatase Assay 
Alkaline phosphatase (ALP) is a membrane bound enzyme that is used as a 
marker for osteogenic differentiation and measuring the bioactivity of the 
BMP-2 being released [217]. The bioactivity of BMP-2 released from the 
yolk-shell particles was studied by determining the ability to induce ALP 
enzymatic activity over basal levels in C2C12 cells (negative controls) after 7 
days of culture, and by comparing the cell response to a BMP-2 dose–response 
effect directly added to the culture medium (positive control). The cell number 
was normalized by measuring protein concentration using a Bradford assay. 
BMP-2 released from silk fibroin core nanoparticles was also studied for 
comparison purpose. The BMP-2 released from the yolk-shell particles was 
able to induce a significant increase in the ALP activity over basal levels in the 
course of 7 days (p<0.01; Fig. 5.5B). The remaining activity of encapsulated 
and released BMP-2 was calculated by comparing it to activity of BMP-2 
when it was added directly into the media (taken as 100% activity over the 
basal levels Fig. 5.5A). The total percentage of BMP-2 released at each time 
point was estimated by using the data observed for the release of BMP-2. 
When the ALP activity was normalized to the amount of BMP-2 present at 
any given instant (added or released) , it was seen that the activity of BMP-2 
added in solution to the culture media and cells decreased over time while the 






Figure 5.5: ALP Assay to monitor BMP-2 activity: A) BMP-2 activity measured in terms of Relative 
ALP activity as compared to ALP activity under the influence of  BMP-2 added in the solution. B) ALP 
activity normalized to the amount of BMP-2 released (n=3 for all data points). 
 
 
5.3.1.3.2 Alizarin Red Staining 
Calcium deposits are an indication of successful differentiation of cells into 
osteoblasts and in vitro bone-formation as undifferentiated myoblasts have no 
extracellular calcium deposits [214]. They can specifically be stained bright 






nanoparticles and yolk-shell particles were used as test groups to study the 
mineralization induced by the BMP-2 released from them. 2x10
6 
pg/mL of 
BMP-2 was added in solution to the positive control group and the amount of 
total BMP-2 added in each well was maintained at the same level using the 
loading efficiency data. Cells grown without the BMP-2 were used as a 
negative control. It was seen that after 7 days of culture, the Alizarin Red 
staining was deep in cells grown with BMP-2 loaded nanoparticles and even 
deeper in cells grown with BMP-2 loaded yolk-shell particles (Fig. 5.6A-C). 
The observations were consistent with the ALP activity data and showed that a 
slow and sustained release of BMP-2 is more effective than BMP-2 added in 
solution, as far as calcium deposits, and as an inference, osteogenic 
differentiation of C2C12 cells are concerned.  
 
Figure 5.6: Alizarin red staining of C2C12 cells: A) Alizarin red staining of C2C12 cells incubated in 
differentiation media and under soluble BMP-2 , B) BMP-2 loaded SF particles and C) BMP-2 loaded 
YSPs . Deeper stains can be seen in cells incubated with BMP-2 loaded SF YSPs as compared to those 









5.3.1.3.3 mRNA Extraction And RT-PCR 
It is known that BMP-2 inhibits the differentiation of C2C12 cells into 
myogenic lineage and promotes osteogenic differentiation [218]. Hence, a 
decrease in myogenic mRNA can be considered an indicator of osteogenic 
differentiation of myoblasts. The mRNA was extracted as mentioned in the 
materials and methods and sections and the concentration was determined by 
using UV absorbance at 260 nm using nanodrop (Thermo Scientific). Cells 
grown under BMP-2 directly added to culture medium were used as positive 
control and cells grown in culture medium were used as a negative control. All 
cultures were carried out in osteogenic differentiation media. An apparent 
decrease in mRNA was observed across all test groups (BMP-2 loaded core 
silk fibroin nanoparticles and yolk-shell particles) over 7 days (Figure 5.7).  
The reduction in mRNA from the initial amount (measured immediately post 
addition of the test groups) was significantly (p<0.01) more for the groups 
containing BMP-2 either dissolved or encapsulated in silk fibroin 
nanoparticles and yolk-shell particles. The groups with the silk fibroin 
nanoparticles and yolk-shell particles showed greater mRNA reduction than 
the group containing BMP-2 in dissolved form in differentiation media and 





Figure 5.7: mRNA reduction in c2c12 cells post osteogenic differentiation: % Reduction in mRNA 
after 1 week of incubation of C2C12 cells in osteogenic differentiation media.  
 
The following genes were used for the gene expression study for osteogenic 
differentiation of C2C12 cells. 
 
Table 5.1: Genes and corresponding primer sequences used for RTPCR. 
 
Gene expressions of RUNX2, osteocalcin, and collagen 1 are critical in early 
stages of bone regeneration [219] RUNX2 is a member of runt-domain gene 
family and introduction of RUNX2 into non-osteoblast cells induced the 
expression of osteoblast specific genes [219].  RUNX2 has been identified as a 
master regulatory gene of the osteoblast differentiation [219]. C2C12 cells 







TTTAGGGCGCATTCCTCATC TGTCCTTGTGGATTAAAAGGACTTG 102 NM_009820 
OCN  TCTGACAAAGCCTTCATGTC AAATAGTGATACCGTAGATG 198 L24431 




normally differentiate along the myogenic lineage and do not express RUNX2 
in the unstimulated condition. Similarly Osteocalcin (OCN) and Collagen 1 
(COL 1) are also used as markers for osteogenic differentiation. 
Here it was shown that the groups containing BMP-2 loaded in YSPs showed 
a significant (p<0.01) increase in relative expression of the genes over a period 
of 1 week for RUNX2, OCN, and COL (Figure 5.8A-C). 
The mRNA reduction and increase in the expression of early osteogenic 
differentiation marker shows that the YSPs are effective in their 
osteoinductive ability by maintaining a sustained release of BMP-2 and 







Figure 5.8: Expression of osteogenic gene markers: A) Relative gene expression of OCN. B) Relative 
gene expression of RUNX 2. C) Relative gene expression of COL 1. * Indicates significant differences. 









5.3.2 Testing the YSP-HA-Thrombin Putty 
5.3.2.1 Cytotoxicity  
Once the non-cytotoxic nature and the osteoinductive potential of the yolk-
shell particles were established, the putty was also tested for cytotoxicity. The 
Alamar Blue reduction assay was conducted in a manner similar to the one 
described in section 5.3.1.1 and the results indicate that the putty shows a 
better reduction in Alamar Blue when compared to that shown by the putty 
made of just hydroxyapatite as the powder phase (Fig. 5.9). Though, the 
percentage reduction of Alamar Blue decreases with time for both groups, the 
decrease is more in case of the hydroxyapatite putty. As it was seen earlier, the 
yolk-shell particles show negligible cytotoxicity and hence their incorporation 
in the putty decreases the innate cytotoxicity of hydroxyapatite. 
Hydroxyapatite has been commonly used in in vivo implantations  and has 
shown osteoconduction, a lack of local and systemic toxicity, no 
inflammation, and no foreign body response  and direct apposition of new 
bone to hydroxyapatite has been shown without an intervening fibrous layer  
[84]. Here it was shown that the toxicity of hydroxyapatite based materials can 











Figure 5.9: Alamar blue reduction in C2C12 cells grown with YSP-HA putty: % Reduction in 
Alamar Blue by HA putty and YSP-HA-Thrombin putty. All results are normalized to control which was 
the same number of cells grown in culture media. 
 
5.3.2.2 Effect on Bone Regeneration 
It was shown earlier that the BMP-2 loaded SF YSPs show an increased 
expression of osteogenic markers in C2C12 cells when compared to cells 
treated with BMP-2 delivered in solution form. Hydroxyapatite is a known 
osteoconductive material [72, 84, 190]. It was important to show that these 
two materials viz. HA and SF YSPs also promote osteogenic differentiation of 
C2C12 cells. As discussed earlier, undifferentiated myoblasts have no 
extracellular calcium deposits, whereas differentiated osteoblasts feature vast 




successful differentiation of cells into osteoblasts and in vitro bone-formation 
[214]. Calcium deposits can specifically be stained bright orange-red using 
Alizarin Red Stain at pH 4.2-4.3. It was a challenge to stain the putty samples 
in culture with Alizarin Red as the surface of the putty, where the cells were 
attached, was rough and the putty had a tendency of absorbing the dye as well. 
Nonetheless, the YSP-HA-Thrombin putty samples showed a deeper red color 
than that shown by HA putty when stained with the dye (Figure 5.10 A,B). In 
order to corroborate the fact that the YSP-HA-Thrombin putty increases the 
amount of extracellular calcium, the calcium content of each well was 
analyzed using Calcium Colorimetric Assay Kit (Biovision). It was seen, that 
both the HA and YSP-HA-Thrombin putty show an increase in calcium 
content over cells which are treated with osteogenic differentiation media 
supplemented with BMP-2 in solution and untreated cells grown in 
differentiation culture media (Figure 5.11 C). The YSPs were loaded at a 
loading of 0.24% BMP-2 (by weight) and an equivalent amount of BMP-2 
was added to the positive control. The YSP-HA-Thrombin putty shows an 
increased level of calcium content over its HA counterpart. Hence it is 
reasonable to assume that a HA putty created by using BMP-2 loaded YSPs 








Figure 5.10: Effect of putty on mineralization of C2C12 cells: A) Alizarin red staining of C2C12 cells 
grown on HA putty. B) Alizarin red staining of C2C12 Cells grown on YSP-HA-Thrombin putty. C) 
Quantification of Calcium content  (n=3 for all data points). 
 
5.4 Conclusion 
The main aim of this chapter was to test the yolk-shell particles and the YSP-
HA-thrombin putty in a simulated biological environment for biocompatibility 
and osteoactive potential. The silk fibroin yolk shell particles developed 
earlier, do not have a negative impact on cell viability. The BMP-2 released 
from the particles was active and keeping in mind the slow and sustained 
release profile demonstrated earlier, proved to be effective in initiating and 
affecting differentiation of cells into osteogenic lineage. This was 
demonstrated by ALP activity and increase in expression of osteogenic 
differentiation markers. When these BMP-2 laden YSPs were used in 
conjunction with HA, to make a putty, they improved upon the innate 
biocompatibility and osteogenic differentiation potential of commercially used 



























































Chapter-6: Conclusions and Future Work 
 
6.1 Conclusions 
A moldable putty comprising novel silk fibroin yolk shell particles, 
hydroxyapatite and thrombin was developed in this project to provide 
hemostasis and aid in bone repair. The putty was developed in a sequential 
manner by synthesizing BMP-2 loaded silk fibroin yolk-shell particles 
followed by mixing with hydroxyapatite using thrombin supplemented binding 
agent. Various specific aims and milestones were envisaged to structure and 
monitor the development of the material.  
It was shown that the silk fibroin yolk-shell particles developed, possessed a 
unique core-void-shell configuration with the shell and BMP-2 laden cores 
being made of silk fibroin. The purpose of the configuration was to protect the 
BMPs from organic solvents used during synthesis and also to provide a more 
sustained release profile. The size of these yolk-shell particles ranged from 
400 nm to 2 µm and the synthesis parameters of these particles could be 
altered to optimize the size, shape and polydispersity of the particles. It was 
shown that these particles possess excellent loading efficiency for BMP-2. The 
release of BMP-2 from these YSPs was shown to be more sustained than that 
observed from silk fibroin core nanoparticles loaded with the same amount of 
BMP-2. 
When tested with C2C12 cells, these particles showed little or no cytotoxicity 
and maintained the functionality of the BMP-2 which was being released. 




ALP activity when compared to silk fibroin core nanoparticles (which did not 
possess the yolk shell structure). These particles also promoted osteogenic 
differentiation of C2C12 cells under a differentiation media by increasing gene 
expression of early osteogenic markers. The cells incubated under BMP-2 
loaded YSPs showed higher extra cellular calcium indicating better 
mineralization than cells incubated under BMP-2 administered in solution or 
via SF nanoparticles. 
The next step was to incorporate these particles in a moldable putty. It was 
seen that the YSPs prepared in chapter 3, could be used in combination with 
HA (a known osteoconductive material) and a suitable binding agent to form a 
putty with good mechanical and handling properties. This putty could release 
the BMP-2 over a sustained period of time. Thrombin, which was present in 
the binding medium of the putty, paved way for the hemostatic nature of the 
putty and immediate blood clotting could be seen when blood came in contact 
with it. Hydroxyapatite is osteoconductive in nature but has no osteoinductive 
components. The incorporation of BMP-2 loaded SF YSPs not only improved 
upon the innate biocompatibility of HA (if it were to be used alone) as 
indicated by decreased cytotoxicity levels over conventional HA putty, but 
also imparted osteoinductive properties to it which was shown by improved 
mineralization by C2C12 cells. These results, which were in accordance with 
the initial hypothesis, demonstrate the material’s potential to be used as a bone 






6.2. Future Work and Potential Applications 
Even though the intended purpose of the material is to assist surgeons during 
minimally invasive orthopedic surgeries, the product developed and the 
techniques used during its development can be used in multidisciplinary fields. 
Firstly, a modified oil in water emulsification technique was developed which 
eliminates the use of harsh organic solvents during synthesis of polymeric 
nanoparticles and capsules. This could pave way for a more potent and 
effective manner of incorporating growth factors and other delicate proteins as 
cargoes in polymeric particles. 
Further, the sequential loading and encapsulation technique to create the yolk 
shell particles can also be used to deliver a variety of cargoes to their desired 
location. This hierarchical scheme paves way for different cargoes to be 
incorporated at different stages of synthesis and hence can provide a template 
for spatially and temporally controlling release of various substances. Since 
these YSPs showed a more sustained release of incorporated proteins, they can 
also be used to delay the release of cargo if required, by altering the synthesis 
parameters which control size and distribution of these particles. 
During the development of the YSP-HA-Thrombin putty, silk fibroin solution 
was used as a binding medium. SF has not been used for this purpose to the 
best of our knowledge. Also, the same protein, SF, is used 3 times in different 
forms for the synthesis of the putty; once to synthesize SF nanoparticles, then 
to synthesize SF YSPs and finally as a binding agent to bind the components 
of the putty. This fact can minimize the material costs of related products. It 




SF as a binding medium were excellent and hence this method can also be 
used to make dental and orthopedic cements and filler materials. 
The method used to test the hemostatic ability of the putty is also novel. To the 
best of our knowledge, a sandwich microchannel device to monitor and record 
blood flow in contact with a moldable material has not been developed. This 
technique can minimize the amount of blood required by traditional techniques 
to test the hemostatic potential of a material. 
In this project, the product was assessed by using in vitro models. In future, 
the product needs to be tested using animal models such as rabbit, porcine or 
goat models.  
To sum up, this product can overcome the major shortcoming of uncertainty in 
achieving fusion in minimally invasive orthopedic surgeries and the 
techniques used in the development of the material can be tailored to suit 
different applications. The product can assist surgeons to improve the bone 
regenerative process during minimally invasive surgeries by controlling blood 
loss and delivering a concentration of bone growth factors at the same time to 
a localized area. The patient is also likely to be benefitted by the advantages of 
minimally invasive surgery without the need to take additional bone grafts, 
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